

***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:51:17 ON 30 JUN 2004

=> file biosis,caba,caplus,embase,japio,lifesci,medline,scisearch,uspatfull

=> e skeiky yasir/au

E1 42 SKEIKY Y A/AU
E2 207 SKEIKY Y A W/AU
E3 20 --> SKEIKY YASIR/AU
E4 13 SKEIKY YASIR A/AU
E5 243 SKEIKY YASIR A W/AU
E6 1 SKEIKY YASIR AW/AU
E7 1 SKEIKY YASSIR A/AU
E8 4 SKEIL D/AU
E9 8 SKEIL D A/AU
E10 6 SKEIL D D/AU
E11 2 SKEIM P/AU
E12 2 SKEIN E/AU

=> s e1-e7 and mycobact?

L1 202 ("SKEIKY Y A"/AU OR "SKEIKY Y A W"/AU OR "SKEIKY YASIR"/AU OR
"SKEIKY YASIR A"/AU OR "SKEIKY YASIR A W"/AU OR "SKEIKY YASIR
AW"/AU OR "SKEIKY YASSIR A"/AU) AND MYCOBACT?

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 104 DUP REM L1 (98 DUPLICATES REMOVED)

=> s l2 and ((mtb39)or(mtb32a)or(mtb59f)or(mtb72f)or(mtb72fmutsa))

L3 31 L2 AND ((MTB39) OR (MTB32A) OR (MTB59F) OR (MTB72F) OR (MTB72FMUTSA)

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 31 DUP REM L3 (0 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 31 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:372587 CAPLUS

DN 140:390287

TI Construction of fusion proteins of ***mycobacterium*** tuberculosis
antigens and use as vaccines

IN ***Skeiky, Yasir*** ; Reed, Steven; Alderson, Mark

PA USA

SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 597,796.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004086523	A1	20040506	US 2001-886349	20010620
PRAI	US 2000-597796	A2	20000620		
	US 2001-265737P	P	20010201		

AB The present invention relates to compns. and fusion proteins contg. at
least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding
such compns. and fusion proteins. The compns. of the invention increase
serol. sensitivity of sera from individuals infected with tuberculosis,
and methods for their use in the diagnosis, treatment, and prevention of
tuberculosis infection.

L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:403055 CAPLUS

DN 140:405473

TI Lung tumor proteins, polynucleotides and antibodies for lung cancer
therapy and diagnosis

IN Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.;
Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun;

Skeiky, Yasir A. W. ; Henderson, Robert A.; McNeill, Patricia D.

PA Corixa Corporation, USA

SO U.S., 230 pp., Cont.-in-part of U.S. 6,531,315.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 19

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	US 6737514	B1	20040518	US 2000-630940	20000802
	US 2003119763	A1	20030626	US 1999-466396	19991217
	US 6696247	B2	20040224		
	US 6706262	B1	20040316	US 1999-476496	19991230
	US 6482597	B1	20021119	US 2000-480884	20000110
	US 6518256	B1	20030211	US 2000-542615	20000404
	US 6531315	B1	20030311	US 2000-606421	20000628
	US 6426072	B1	20020730	US 2000-643597	20000821
	US 2002052329	A1	20020502	US 2000-735705	20001212
	WO 2002000174	A2	20020103	WO 2001-US21065	20010628
	WO 2002000174	A3	20030410		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004513615	T2	20040513	JP 2002-504957	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204

PRAI	US 1999-285479	A2	19990402		
	US 1999-466396	A2	19991217		
	US 1999-476496	A2	19991230		
	US 2000-480884	A2	20000110		
	US 2000-510376	A2	20000222		
	US 2000-542615	A2	20000404		
	US 2000-606421	A2	20000628		
	US 1998-40802	B2	19980318		
	US 1998-123912	A2	19980727		
	US 1998-221107	A1	19981222		
	WO 1999-US5798	A1	19990317		
	US 2000-630940	A2	20000802		
	US 2000-643597	A2	20000821		
	US 2000-662786	A2	20000915		
	US 2000-685696	A2	20001009		
	US 2000-735705	A	20001212		
	US 2001-850716	A	20010507		
	US 2001-897778	A2	20010628		
	WO 2001-US21065	W	20010628		
	US 2001-7700	A2	20011130		
	US 2002-117982	A2	20020405		

AB Compns. and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compns. may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. The lung tumor proteins are identified and characterized from cDNA libraries of human lung squamous cell carcinoma and human lung adenocarcinoma. Alternatively, a therapeutic compn. may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 31 USPATFULL on STN

AN 2004:18375 USPATFULL

TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and their uses

IN ***Skeiky, Yasir***, Bellevue, WA, UNITED STATES
Alderson, Mark, Bainbridge Island, WA, UNITED STATES

Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES

PI US 2004013677 A1 20040122

AI US 2003-359459 A1 20030205 (10)

RLI Continuation of Ser. No. US 1998-223040, filed on 30 Dec 1998, GRANTED, Pat. No. US 6544522

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 21 Drawing Page(s)

LN.CNT 1244

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins of
 Mycobacterium tuberculosis antigens. In particular, it relates to two fusion proteins, each of which contains three individual M. tuberculosis antigens, and a fusion protein of two M. tuberculosis antigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.

L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:462305 CAPLUS

TI Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, ***Mtb72F*** , Delivered as Naked DNA or Recombinant Protein

AU ***Skeiky, Yasir A. W.*** ; Alderson, Mark R.; Owendale, Pamela J.; Guderian, Jeffrey A.; Brandt, Lise; Dillon, Davin C.; Campos-Neto, Antonio; Lobet, Yves; Dalemans, Wilfried; Orme, Ian M.; Reed, Steven G.

CS Corixa Corp., Seattle, WA, 98104, USA

SO Journal of Immunology (2004), 172(12), 7618-7628
 CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

AB Key Ags of ***Mycobacterium*** tuberculosis initially identified in the context of host responses in healthy purified protein deriv.-pos. donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, ***Mtb72F*** , codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C- ***Mtb39*** -Mtb32N. Immunization of C57BL/6 mice with ***Mtb72F*** DNA resulted in the generation of IFN-.gamma. responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with ***Mtb72F*** protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-.gamma. response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of ***Mtb72F*** protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-.gamma. and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of ***Mtb72F*** immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with ***Mtb72F*** , delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 yr) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization. ***Mtb72F*** in AS02A formulation is currently in phase I clin. trial, making it the first recombinant tuberculosis vaccine to be tested in humans.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:678617 CAPLUS

DN 139:212869

TI Fusion proteins of ***Mycobacterium*** tuberculosis and use as vaccine for antituberculosis infection

IN ***Skeiky, Yasir*** ; Guderian, Jeff; Reed, Steven

PA Corixa Corporation, USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070187	A2	20030828	WO 2003-US4903	20030218
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003235593	A1	20031225	US 2003-369983	20030218
PRAI	US 2002-357351P	P	20020215		

AB The present invention relates to compns. and fusion proteins contg. at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compns. and fusion proteins. The compns. of the invention increase serol. sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:390752 CAPLUS

DN 138:396181

TI Immunoreactive nucleic acids and proteins for treatment and diagnosis of chlamydial infection

IN ***Skeiky, Yasir A. W.*** ; Scholler, John

PA Corixa Corporation, USA

SO U.S., 233 pp., Cont.-in-part of U.S. 6,432,916.

CODEN: USXXAM

DT Patent
LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6565856	B1	20030520	US 2000-598419	20000620
	US 6166177	A	20001226	US 1998-208277	19981208
	US 6447779	B1	20020910	US 1999-288594	19990408
	US 6555115	B1	20030429	US 1999-410568	19991001
	US 6432916	B1	20020813	US 2000-556877	20000419
	US 6448234	B1	20020910	US 2000-620412	20000720
	WO 2001040474	A2	20010607	WO 2000-US32919	20001204
	WO 2001040474	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1238084	A2	20020911	EP 2000-980969	20001204
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003515343	T2	20030507	JP 2001-542539	20001204
	BR 2000016066	A	20030610	BR 2000-16066	20001204
	NO 2002002592	A	20020719	NO 2002-2592	20020531
PRAI	US 1998-208277	A2	19981208		
	US 1999-288594	A2	19990408		
	US 1999-410568	A2	19991001		
	US 1999-426571	A1	19991022		
	US 1999-454684	A2	19991203		
	US 2000-556877	A2	20000419		
	US 2000-598419	A2	20000620		

WO 2000-US32919 W 20001204

AB Comps. and methods for the diagnosis and treatment of Chlamydial infection are disclosed. Chlamydia antigens of the present invention were isolated by expression cloning of genomic DNA libraries of Chlamydia trachomatis LGV II and Chlamydia pneumonia strain TWAR, and were shown to induce PBMC proliferation and interferon- γ prodn. in immunoreactive T cell lines. The comps. provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. In particular, the invention provides the C. trachomatis polymorphic membrane protein PmpD. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Various Pmp/Ra12 fusion constructs are also provided, where Ra12 comprises residues 192-323 of the ***Mycobacterium*** tuberculosis ***MTB32A*** serine proteinase. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 31 USPATFULL on STN
AN 2003:334717 USPATFULL
TI Fusion proteins of ***Mycobacterium*** tuberculosis
IN ***Skeiky, Yasir***, Bellevue, WA, UNITED STATES
Guderian, Jeff, Lynwood, WA, UNITED STATES
Reed, Steven, Bellevue, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003235593 A1 20031225
AI US 2003-369983 A1 20030218 (10)
PRAI US 2002-357351P 20020215 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 85
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 2856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and fusion proteins containing at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L4 ANSWER 8 OF 31 USPATFULL on STN
AN 2003:250508 USPATFULL
TI Heterologous fusion protein constructs comprising a Leishmania antigen
IN ***Skeiky, Yasir***, Bellevue, WA, UNITED STATES
Brannon, Mark, Seattle, WA, UNITED STATES
Guderian, Jeffrey, Lynwood, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003175294 A1 20030918
AI US 2002-98732 A1 20020313 (10)
PRAI US 2001-275837P 20010313 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 82
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 6952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant nucleic acid molecule encoding a fusion polypeptide, wherein the recombinant nucleic acid comprises a heterologous polynucleotide sequence encoding an antigen or an antigenic fragment; and a Leishmania polynucleotide sequence encoding a polypeptide or fragment thereof, wherein the Leishmania polynucleotide

is selected from the group consisting of TSA polynucleotide, LeIF polynucleotide, M15 polynucleotide, and 6H polynucleotide. The invention also provides an expression cassette comprising the recombinant nucleic acid molecule, host cells comprising the expression cassette, compositions, fusion polypeptides, and methods of their use in diagnosis or in generating a protective immune response in hosts.

L4 ANSWER 9 OF 31 USPATFULL on STN

AN 2003:225278 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Hepler, William T., Seattle, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Vinals y de Bassols, Carlota, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Deng, Ta, Edmonds, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003157089 A1 20030821

AI US 2002-144678 A1 20020509 (10)

RLI Continuation-in-part of Ser. No. US 2001-12896, filed on 10 Dec 2001,
PENDING Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun
2001, PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on
9 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-780669,
filed on 9 Feb 2001, PENDING Continuation-in-part of Ser. No. US
2001-759143, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser.
No. US 2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part
of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000,
PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep
2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on
29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215,
filed on 9 Aug 2000, PENDING Continuation-in-part of Ser. No. US
2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser.
No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part
of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING
Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000,
PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed
on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686,
filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US
1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505
Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999,
GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US
1999-288946, filed on 9 Apr 1999, ABANDONED Continuation-in-part of Ser.
No. US 1999-232149, filed on 15 Jan 1999, GRANTED, Pat. No. US 6465611
Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998,
PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul
1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on
25 Feb 1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser.
No. US 1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,

ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25 Feb 1997, ABANDONED

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 8995

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 10 OF 31 USPATFULL on STN

AN 2003:213274 USPATFULL

TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and their uses

IN Reed, Steven G., Bellevue, WA, UNITED STATES
Skeiky, Yasir A., Bellevue, WA, UNITED STATES
Dillon, Davin C., Redmond, WA, UNITED STATES
Alderson, Mark, Bainbridge, WA, UNITED STATES
Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003147911 A1 20030807

AI US 2003-359460 A1 20030205 (10)

RLI Continuation of Ser. No. US 1999-287849, filed on 7 Apr 1999, ABANDONED
Continuation-in-part of Ser. No. US 1998-223040, filed on 30 Dec 1998, GRANTED, Pat. No. US 6544522 Continuation-in-part of Ser. No. US 1998-56556, filed on 7 Apr 1998, GRANTED, Pat. No. US 6350456
Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-942578, filed on 1 Oct 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-818112, filed on 13 Mar 1997, GRANTED, Pat. No. US 6290969

DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 68 Drawing Page(s)
LN.CNT 3971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins containing at least two ***Mycobacterium*** tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

L4 ANSWER 11 OF 31 USPATFULL on STN

AN 2003:93586 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Fanger, Neil, Seattle, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Durham, Margarita, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
 Peckham, David W., Seattle, WA, UNITED STATES
 Cai, Feng, Lake Forest Park, WA, UNITED STATES
 Foy, Teresa M., Federal Way, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003064947 A1 20030403
 AI US 2001-7700 A1 20011130 (10)
 RLI Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May
 2001, PENDING Continuation-in-part of Ser. No. US 2000-735705, filed on
 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-685696,
 filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US
 2000-662786, filed on 15 Sep 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-643597, filed on 21 Aug 2000, PENDING Continuation-in-part
 of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr
 2000, PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on
 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884,
 filed on 10 Jan 2000, PENDING Continuation-in-part of Ser. No. US
 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser.
 No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part
 of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING
 Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998,
 PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul
 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US
 1998-40802, filed on 18 Mar 1998, PENDING
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 16032
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.
 L4 ANSWER 12 OF 31 USPATFULL on STN
 AN 2003:268131 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of prostate
 cancer
 IN Xu, Jiangchun, Bellevue, WA, United States
 Dillon, Davin C., Issaquah, WA, United States
 Mitcham, Jennifer L., Redmond, WA, United States
 Harlocker, Susan L., Seattle, WA, United States
 Jiang, Yuqiu, Kent, WA, United States
 Kalos, Michael D., Seattle, WA, United States
 Fanger, Gary R., Mill Creek, WA, United States
 Retter, Marc W., Carnation, WA, United States
 Stolk, John A., Bothell, WA, United States
 Day, Craig H., Seattle, WA, United States
 Vedvick, Thomas S., Federal Way, WA, United States
 Carter, Darrick, Seattle, WA, United States
 Li, Samuel X., Redmond, WA, United States
 Wang, Aijun, Issaquah, WA, United States
 Skeiky, Yasir A. W., Bellevue, WA, United States
 Hepler, William T., Seattle, WA, United States
 Henderson, Robert A., Edmonds, WA, United States
 PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 6630305 B1 20031007

AI US 2000-685166 20001010 (9)

RLI Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000
Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000
Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000
Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug 2000
Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000
Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000
Continuation-in-part of Ser. No. US 2000-510737, filed on 12 May 2000
Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000
Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000,
now abandoned Continuation-in-part of Ser. No. US 2000-483672, filed on
14 Jan 2000 Continuation-in-part of Ser. No. US 1999-443686, filed on 18
Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-439313,
filed on 12 Nov 1999, now patented, Pat. No. US 6329505

DT Utility

FS GRANTED

EXNAM Primary Examiner: Brusca, John S.; Assistant Examiner: Zhou, Shubo

LREP Seed IP Law Group

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 7044

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly prostate cancer, are disclosed. Illustrative compositions
comprise one or more prostate-specific polypeptides, immunogenic
portions thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:716453 CAPLUS

DN 137:246530

TI Fusion proteins of Leishmania antigens and antigens of pathogens for
diagnostic or vaccine use

IN ***Skeiky, Yasir*** ; Brannon, Mark; Guderian, Jeffrey

PA Corixa Corporation, USA

SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072792	A2	20020919	WO 2002-US8223	20020313
	WO 2002072792	C1	20030807		
	WO 2002072792	C2	20040408		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003175294	A1	20030918	US 2002-98732	20020313
PRAI	US 2001-275837P	P	20010313		

AB Fusion proteins of antigens of Leishmania and foreign antigens that may be
useful in the diagnosis, prophylaxis or treatment of disease are
described. The Leishmania antigen may be TSA (thiol-specific
antioxidant), LeIF (initiation factor 4A), M15 or 6H. The invention also
provides an expression cassette comprising the recombinant nucleic acid
mol., host cells comprising the expression cassette, compns., fusion
polypeptides, and methods of their use in diagnosis or in generating a
protective immune response in hosts. The genes may be codon optimized for
expression in a specific host. Specifically, fusion proteins with
antigens of ***Mycobacterium*** tuberculosis are described.

Construction of codon optimized genes for fusion proteins of Leishmania antigens and ***Mycobacterium*** tuberculosis antigens and their expression in HEK cells is demonstrated.

L4 ANSWER 14 OF 31 USPATFULL on STN
AN 2002:337931 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Bassols, Carlota Vinals y de, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES
PI US 2002193296 A1 20021219
AI US 2001-895814 A1 20010629 (9)
RLI Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May 2001,
PENDING Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb
2001, PENDING Continuation-in-part of Ser. No. US 2001-759143, filed on
12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-709729,
filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser.
No. US 2000-679426, filed on 2 Oct 2000, PENDING Continuation-in-part of
Ser. No. US 2000-657279, filed on 6 Sep 2000, PENDING
Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000,
PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug
2000, PENDING Continuation-in-part of Ser. No. US 2000-605783, filed on
27 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-593793,
filed on 13 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-570737, filed on 12 May 2000, PENDING Continuation-in-part of Ser.
No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of
Ser. No. US 2000-536857, filed on 27 Mar 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000,
PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed
on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US
1999-352616, filed on 13 Jul 1999, PENDING Continuation-in-part of Ser.
No. US 1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of
Ser. No. US 1999-232149, filed on 15 Jan 1999, PENDING
Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998,
PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul
1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on
25 Feb 1998, PATENTED Continuation-in-part of Ser. No. US 1998-20956,
filed on 9 Feb 1998, PATENTED Continuation-in-part of Ser. No. US
1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser.
No. US 1997-806099, filed on 25 Feb 1997, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 7973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 15 OF 31 USPATFULL on STN

AN 2002:337404 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
y de Bassols, Carlota Vinals, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES

PI US 2002192763 A1 20021219

AI US 2001-895793 A1 20010629 (9)

RLI Continuation-in-part of Ser. No. US 2001-822827, filed on 28 Mar 2001,
PENDING Continuation-in-part of Ser. No. US 2000-679272, filed on 4 Oct
2000, PENDING

PRAI US 2000-157455P 20000417 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 7578

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 16 OF 31 USPATFULL on STN

AN 2002:323085 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Vinals y de Bassols, Carlota, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002183251 A1 20021205

AI US 2001-12896 A1 20011210 (10)

RLI Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun 2001,
PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May
2001, PENDING Continuation-in-part of Ser. No. US 2001-780669, filed on
9 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-759143,
filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US
2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser.
No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part
of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000,
PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug
2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on
9 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783,
filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser.
No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part
of Ser. No. US 2000-568100, filed on 9 May 2000, PENDING
Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed on 14
Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed
on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US
1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505
Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999,
GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US
1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser.
No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part
of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998,
PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb
1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US
1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,
ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25
Feb 1997, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 8810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly prostate cancer, are disclosed. Illustrative compositions
comprise one or more prostate-specific polypeptides, immunogenic
portions thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly prostate cancer.

AN 2002:322030 USPATFULL
 TI Compounds for immunotherapy and diagnosis of colon cancer and methods
 for their use
 IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 Benson, Darin R., Seattle, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 Wang, Tongtong, Medina, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 Smith, Carole L., Seattle, WA, UNITED STATES
 King, Gordon E., Shoreline, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Clapper, Jonathan D., Seattle, WA, UNITED STATES
 Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2002182191 A1 20021205
 AI US 2001-25380 A1 20011219 (10)
 RLI Continuation-in-part of Ser. No. US 2001-922217, filed on 3 Aug 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-833263, filed on 10 Apr
 2001, PENDING Continuation-in-part of Ser. No. US 2000-649811, filed on
 28 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-609448,
 filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US
 2000-575251, filed on 19 May 2000, ABANDONED Continuation-in-part of
 Ser. No. US 2000-519444, filed on 6 Mar 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2000-504629, filed on 15 Feb 2000,
 ABANDONED Continuation-in-part of Ser. No. US 2000-480321, filed on 10
 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-476296,
 filed on 30 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US
 1999-454150, filed on 2 Dec 1999, ABANDONED Continuation-in-part of Ser.
 No. US 1999-444252, filed on 19 Nov 1999, PENDING Continuation-in-part
 of Ser. No. US 1999-401064, filed on 22 Sep 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-347496, filed on 2 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1998-221298, filed on 23 Dec
 1998, GRANTED, Pat. No. US 6284241
 PRAI WO 1999-US30909 19991223
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5203
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer, such
 as colon cancer, are disclosed. Compositions may comprise one or more
 colon tumor proteins, immunogenic portions thereof, or polynucleotides
 that encode such portions. Alternatively, a therapeutic composition may
 comprise an antigen presenting cell that expresses a colon tumor
 protein, or a T cell that is specific for cells expressing such a
 protein. Such compositions may be used, for example, for the prevention
 and treatment of diseases such as colon cancer. Diagnostic methods based
 on detecting a colon tumor protein, or mRNA encoding such a protein, in
 a sample are also provided.
 L4 ANSWER 18 OF 31 USPATFULL on STN
 AN 2002:295321 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of breast cancer
 IN Frudakis, Tony N., Sarasota, FL, UNITED STATES
 Reed, Steven G., Bellevue, WA, UNITED STATES
 Smith, John M., Columbia Heights, MN, UNITED STATES
 Misher, Lynda E., Seattle, WA, UNITED STATES
 Dillon, Davin C., Issaquah, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES
 Day, Craig H., Shoreline, WA, UNITED STATES
 Li, Samuel X., Redmond, WA, UNITED STATES
 Deng, Ta, Edmonds, WA, UNITED STATES
 PI US 2002165371 A1 20021107
 AI US 2001-924400 A1 20010807 (9)
 RLI Continuation-in-part of Ser. No. US 2001-810936, filed on 16 Mar 2001,
 PENDING Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct
 2000, PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on
 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505,
 filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US
 2000-534825, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser.
 No. US 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part
 of Ser. No. US 1999-289198, filed on 9 Apr 1999, PENDING
 Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998,
 GRANTED, Pat. No. US 6344550 Continuation-in-part of Ser. No. US
 1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054
 Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997,
 ABANDONED A 371 of International Ser. No. WO 1997-US485, filed on 10 Jan
 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-585392, filed on
 11 Jan 1996, ABANDONED
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 22 Drawing Page(s)
 LN.CNT 8977
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly breast cancer, are disclosed. Illustrative compositions
 comprise one or more breast tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly breast cancer.
 L4 ANSWER 19 OF 31 USPATFULL on STN
 AN 2002:157081 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of prostate
 cancer
 IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Dillon, Davin C., Issaquah, WA, UNITED STATES
 Mitcham, Jennifer L., Redmond, WA, UNITED STATES
 Harlocker, Susan L., Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 Day, Craig H., Seattle, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Li, Samuel X., Redmond, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 Hural, John, Bainbridge Island, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Houghton, Raymond L., Bothell, WA, UNITED STATES
 de Bassols, Carlota Vinals, Rixensart, BELGIUM
 PI US 2002081680 A1 20020627
 AI US 2001-822827 A1 20010328 (9)
 RLI Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb 2001,
 PENDING Continuation-in-part of Ser. No. US 2000-679272, filed on 4 Oct
 2000, PENDING
 PRAI US 2000-157455P 20000417 (60)
 DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 7692

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 20 OF 31 USPATFULL on STN

AN 2002:133434 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Frudakis, Tony N., Sarasota, FL, UNITED STATES

Reed, Steven G., Bellevue, WA, UNITED STATES

Smith, John M., Columbia Heights, MN, UNITED STATES

Misher, Lynda E., Seattle, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Day, Craig H., Seattle, WA, UNITED STATES

PI US 2002068285 A1 20020606

AI US 2001-810936 A1 20010316 (9)

RLI Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-534825, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-289198, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998, PENDING Continuation-in-part of Ser. No. US 1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054 Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-700014, filed on 20 Aug 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-585392, filed on 11 Jan 1996, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 22 Drawing Page(s)

LN.CNT 8540

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L4 ANSWER 21 OF 31 USPATFULL on STN

AN 2002:119860 USPATFULL

TI Compounds and methods for treatment and diagnosis of chlamydial infection

IN Bhatia, Ajay, Seattle, WA, UNITED STATES

Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Probst, Peter, Seattle, WA, UNITED STATES

PI US 2002061848 A1 20020523

AI US 2001-841132 A1 20010423 (9)
 RLI Continuation-in-part of Ser. No. US 2000-620412, filed on 20 Jul 2000,
 UNKNOWN
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 11 Drawing Page(s)
 LN.CNT 5318
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds and methods for the diagnosis and treatment of Chlamydial
 infection are disclosed. The compounds provided include polypeptides
 that contain at least one antigenic portion of a Chlamydia antigen and
 DNA sequences encoding such polypeptides. Pharmaceutical compositions
 and vaccines comprising such polypeptides or DNA sequences are also
 provided, together with antibodies directed against such polypeptides.
 Diagnostic kits containing such polypeptides or DNA sequences and a
 suitable detection reagent may be used for the detection of Chlamydial
 infection in patients and in biological samples.
 L4 ANSWER 22 OF 31 USPATFULL on STN
 AN 2002:99428 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Wang, Tongtong, Medina, WA, UNITED STATES
 Fan, Liqun, Bellevue, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 Bangur, Chaitanya S., Seattle, WA, UNITED STATES
 Hosken, Nancy A., Seattle, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Li, Samuel X., Redmond, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 McNeill, Patricia D., Des Moines, WA, UNITED STATES
 Fanger, Neil, Seattle, WA, UNITED STATES
 PI US 2002052329 A1 20020502
 AI US 2000-735705 A1 20001212 (9)
 RLI Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep
 2000, PENDING Continuation-in-part of Ser. No. US 2000-643597, filed on
 21 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-630940,
 filed on 2 Aug 2000, PENDING Continuation-in-part of Ser. No. US
 2000-606421, filed on 28 Jun 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-542615, filed on 4 Apr 2000, PENDING Continuation-in-part of
 Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000,
 PENDING Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec
 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on
 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479,
 filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US
 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser.
 No. US 1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695
 Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998,
 PENDING
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 13060
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed

compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L4 ANSWER 23 OF 31 USPATFULL on STN
AN 2002:99081 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Des Moines, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
PI US 2002051977 A1 20020502
AI US 2001-780669 A1 20010209 (9)
RLI Continuation-in-part of Ser. No. US 2001-759143, filed on 12 Jan 2001,
PENDING Continuation-in-part of Ser. No. US 2000-709729, filed on 9 Nov
2000, PENDING Continuation-in-part of Ser. No. US 2000-685166, filed on
10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426,
filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US
2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser.
No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part
of Ser. No. US 2000-636215, filed on 10 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000,
PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-510737, filed on
1 May 2000, GRANTED, Pat. No. US 6219981 Continuation-in-part of Ser.
No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of
Ser. No. US 2000-536857, filed on 27 Mar 2000, PENDING
Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000,
PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed
on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-352616,
filed on 13 Jul 1999, PENDING Continuation-in-part of Ser. No. US
1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser.
No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part
of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998,
PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb
1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US
1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,
ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25
Feb 1997, ABANDONED Continuation-in-part of Ser. No. WO 1998-US3492,
filed on 25 Feb 1998, UNKNOWN Continuation-in-part of Ser. No. WO
1999-US15838, filed on 14 Jul 1999, UNKNOWN
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 7556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly prostate cancer, are disclosed. Illustrative compositions

comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 24 OF 31 USPATFULL on STN
AN 2002:37531 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yugu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
PI US 2002022248 A1 20020221
AI US 2001-759143 A1 20010112 (9)
RLI Continuation-in-part of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on 10 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999, PENDING Continuation-in-part of Ser. No. US 1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb 1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US 1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562 Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25 Feb 1997, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 7383
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed

compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 25 OF 31 USPATFULL on STN
AN 2002:188122 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Wang, Tongtong, Medina, WA, United States
Fan, Liqun, Bellevue, WA, United States
Kalos, Michael D., Seattle, WA, United States
Bangur, Chaitanya S., Seattle, WA, United States
Hosken, Nancy A., Seattle, WA, United States
Fanger, Gary R., Mill Creek, WA, United States
Li, Samuel X., Redmond, WA, United States
Wang, Aijun, Issaquah, WA, United States
Skeiky, Yasir A. W., Bellevue, WA, United States
Henderson, Robert A., Edmonds, WA, United States
McNeill, Patricia D., Des Moines, WA, United States
PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6426072 B1 20020730
AI US 2000-643597 20000821 (9)
RLI Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000
DT Utility
FS GRANTED
EXNAM Primary Examiner: Borin, Michael; Assistant Examiner: Zhou, Shubo
LREP Seed Intellectual Property Law Group PLLC
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 12270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:731001 CAPLUS
DN 135:284066
TI Nucleic acids and proteins associated with human prostate cancer and their uses in therapy and diagnosis
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary Richard; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; ***Skeiky, Yasir A. W.***; Hepler, William T.; Henderson, Robert A.
PA Corixa Corporation, USA
SO PCT Int. Appl., 579 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 28

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001073032	A2	20011004	WO 2001-US9919	20010327
WO 2001073032	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6512094	B1	20030128	US 2000-593793	20000613

US 6620922	B1	20030916	US 2000-636215	20000810
US 6630305	B1	20031007	US 2000-685166	20001010
AU 2001049549	A5	20011008	AU 2001-49549	20010327
EP 1311673	A2	20030521	EP 2001-922786	20010327

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004504808	T2	20040219	JP 2001-570749	20010327
PRAI US 2000-536857	A	20000327		
US 2000-568100	A	20000509		
US 2000-570737	A	20000512		
US 2000-593793	A	20000613		
US 2000-605783	A	20000627		
US 2000-636215	A	20000810		
US 2000-651236	A	20000829		
US 2000-657279	A	20000906		
US 2000-679426	A	20001002		
US 2000-685166	A	20001010		
US 2000-709729	A	20001109		
US 1997-806099	B2	19970225		
US 1997-904804	B2	19970801		
US 1998-20956	A2	19980209		
US 1998-30607	A2	19980225		
US 1998-115453	A2	19980714		
US 1998-159812	A2	19980923		
US 1999-232149	A2	19990115		
US 1999-288946	A2	19990409		
US 1999-352616	A2	19990713		
US 1999-439313	A2	19991112		
US 1999-443686	B2	19991118		
US 2000-483672	A2	20000114		
US 2000-510737	A2	20000501		
WO 2001-US9919	W	20010327		

AB Compns. and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, and polynucleotides that encode such polypeptides as identified by PCR-based cDNA library subtraction. Chromosomal mapping, tissue expression profiling, and prepn. of fusion proteins (esp. with the Ral2 portion of the ***Mycobacterium*** tuberculosis serine protease ***MTB32A***) are carried out. Epitope mapping is carried out on some of the polypeptides (e.g., P501S) to identify immunogenic peptides. Antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides are also provided. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:526194 CAPLUS

DN 135:117956

TI Nucleic acids and polypeptides for the therapy and diagnosis of human prostate cancer

IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Reed, Steven G.; Kalos, Michael D.; Fanger, Gary Richard; Day, Craig H.; Retter, Marc W.; Stolk, John A.; ***Skeiky,***

*** Yasir A. W.*** ; Wang, Aijun; Meagher, Madeleine Joy

PA Corixa Corporation, USA

SO PCT Int. Appl., 543 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051633	A2	20010719	WO 2001-US1574	20010116
	WO 2001051633	A3	20020620		
	WO 2001051633	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1261708 A2 20021204 EP 2001-906582 20010116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001007643 A 20030610 BR 2001-7643 20010116
JP 2003528591 T2 20030930 JP 2001-551207 20010116
NO 2002003402 A 20020829 NO 2002-3402 20020715
PRAI US 2000-483672 A 20000114
WO 2001-US1574 W 20010116
AB Comps. and methods for the therapy and diagnosis of cancer, particularly
prostate cancer, are disclosed. Several hundred prostate-specific
polynucleotides (and their encoded polypeptides) are isolated from human
prostate tumor cDNA libraries by cDNA library subtraction, PCR-based
subtraction, electronic subtraction, and microarray anal. Illustrative
comps. comprise one or more prostate-specific polypeptides, immunogenic
portions thereof, polynucleotides that encode such polypeptides,
antigen-presenting cells that express such polypeptides, and T cells that
are specific for cells expressing such polypeptides. Recombinant systems
are described for the expression of such prostate-specific polypeptides in
Escherichia coli, baculovirus, Saccharomyces cerevisiae, and mammalian
cells. The disclosed comps. are useful, for example, in the diagnosis,
prevention, and/or treatment of diseases, particularly prostate cancer.

L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:417155 CAPLUS
DN 135:45174
TI Antigenic compounds and methods for treatment and diagnosis of Chlamydial
infection
IN Probst, Peter; Bhatia, Ajay; ***Skeiky, Yasir A. W.*** ; Fling, Steven
P.; Scholler, John
PA Corixa Corporation, USA
SO PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040474	A2	20010607	WO 2000-US32919	20001204
WO 2001040474	A3	20020307		
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
US 6432916	B1	20020813	US 2000-556877	20000419
US 6565856	B1	20030520	US 2000-598419	20000620
EP 1238084	A2	20020911	EP 2000-980969	20001204
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
JP 2003515343	T2	20030507	JP 2001-542539	20001204
BR 2000016066	A	20030610	BR 2000-16066	20001204
NO 2002002592	A	20020719	NO 2002-2592	20020531
PRAI US 1999-454684	A	19991203		
US 2000-556877	A	20000419		
US 2000-598419	A	20000620		
US 1998-208277	A2	19981208		
US 1999-288594	A2	19990408		
US 1999-410568	A2	19991001		
US 1999-426571	A2	19991022		
WO 2000-US32919	W	20001204		
AB		Comps. and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The comps. provided include polypeptides that		

contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides from Chlamydia trachomatis and C. pneumoniae isolated using retroviral expression vector systems and subsequent immunol. anal. and epitope mapping. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples. In particular, fusion proteins are constructed from the Chlamydial proteins PmpA, PmpF, PmpH, PmpB, and PmpC fused with amino acid residues 192-323 of the Ra2 ***MTB32A*** serine proteinase from ***Mycobacterium*** tuberculosis.

L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:265565 CAPLUS

DN 134:291103

TI Methods of using a ***Mycobacterium*** tuberculosis coding sequence in gene and protein fusions to facilitate stable and high yield expression of heterologous proteins

IN ***Skeiky, Yasir*** ; Guderian, Jeffrey

PA Corixa Corporation, USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025401	A2	20010412	WO 2000-US27652	20001006
	WO 2001025401	C2	20020926		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 2000079972	A5	20010510	AU 2000-79972	20001006
	JP 2003527830	T2	20030924	JP 2001-528556	20001006
PRAI	US 1999-158585P	P	19991007		
	WO 2000-US27652	W	20001006		

AB The present invention relates generally to nucleic acid and amino acid sequences of a fusion polypeptide comprising a ***Mycobacterium*** tuberculosis polypeptide, and a heterologous polypeptide of interest, expression vectors and host cells comprising such nucleic acids, and methods for producing such fusion polypeptides. In particular, the invention relates to materials and methods of using such M. tuberculosis sequence as a fusion partner to facilitate the stable and high yield expression of recombinant heterologous polypeptides of both eukaryotic and prokaryotic origin. A 14 kD C-terminal fragment (referred to as Ra12) of the ***Mycobacterium*** tuberculosis serine protease ***MTB32A*** can be expressed as a sol. protein. Use of the Ra12 sequences as a fusion partner is illustrated with construction of expression vectors, expression in Escherichia coli, and protein purifn. of a (His-tag) Ra12-DPPD fusion protein. Antiserum raised against the Ra12-DPPD fusion protein recognized the DPPD protein in immunoblotting anal. Ra12-WT1, Ra12-mammaglobin, and Ra12-H9-32A fusion proteins were also constructed and shorter or longer Ra12 sequences were fused with full length human mammaglobin gene sequences.

L4 ANSWER 30 OF 31 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AN 1999:379686 BIOSIS

DN PREV199900379686

TI Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of ***Mycobacterium*** tuberculosis.

AU ***Skeiky, Yasir A. W.*** [Reprint author]; Lodes, Michael J.;

Guderian, Jeffrey A.; Mohamath, Raodoh; Bement, Teresa; Alderson, Mark R.; Reed, Steven G.

CS Corixa Corporation, 1124 Columbia St., Seattle, WA, 98104, USA

SO Infection and Immunity, (Aug., 1999) Vol. 67, No. 8, pp. 3998-4007. print.
 CODEN: INFIBR. ISSN: 0019-9567.

DT Article
 LA English
 OS Genbank-S47170; Genbank-U15180
 ED Entered STN: 13 Sep 1999
 Last Updated on STN: 13 Sep 1999

AB Culture filtrate proteins (CFP) of ***Mycobacterium*** tuberculosis have been shown to contain immunogenic components that elicit at least partial protective immunity against ***Mycobacterium*** infection. To clone genes encoding some of the immunogenic proteins, we made a high-titer rabbit anti-CFP serum and used it to screen an M. tuberculosis genomic expression library in Escherichia coli. In this paper, we describe the molecular cloning of two new protein components of CFP and identified them as members of the serine protease gene family. Their open reading frames contain N-terminal hydrophobic secretory signals consistent with their detection in CFP. The predicted molecular masses of the mature, fully processed forms of both antigens are approx 32 kDa, in agreement with their observed sizes on immunoblots of CFP probed with polyclonal rabbit antisera made to the recombinant proteins. Thus, these proteins have been designated ***MTB32A*** and MTB32B. Interestingly, and despite 66% amino acid sequence homology between the two proteins, polyclonal rabbit antisera made to each of the recombinant proteins were found to be specific for the respective immunizing antigens. The recombinant proteins were also evaluated in in vitro assays with donor peripheral blood mononuclear cells (PBMC) from healthy purified protein derivative (PPD)-positive individuals of diverse ethnic backgrounds. ***MTB32A*** but not MTB32B stimulated PBMC from healthy PPD-positive donors but not from PPD-negative donors to proliferate and secrete gamma interferon. ***MTB32A*** is encoded by a single-copy gene which is present in both virulent and avirulent strains of the M. tuberculosis complex and the BCG strain of ***Mycobacterium*** bovis but absent in the environmental ***mycobacterial*** species tested. In addition, nucleotide sequence comparison of ***mtb32a*** of the avirulent H37Ra strain and the virulent Erdman strain, as well as with the corresponding sequences (identified in the databases) of strain H37Rv and the clinical isolate CSU93, revealed 100% identity. ***MTB32A***, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during ***Mycobacterium*** spp. infection is discussed.

L4 ANSWER 31 OF 31 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:327567 BIOSIS
 DN PREV199900327567

TI Molecular characterization and human T-Cell responses to a member of a novel ***Mycobacterium*** tuberculosis ***mtb39*** gene family.

AU Dillon, Davin C. [Reprint author]; Alderson, Mark R.; Day, Craig H.; Lewinsohn, David M.; Coler, Rhea; Bement, Teresa; Campos-Neto, Antonio; ***Skeiky, Y. A. W.***; Orme, Ian M.; Roberts, Alan; Steen, Sean; Dalemans, Wilfried; Badaro, Roberto; Reed, Steven G.

CS Corixa Corporation, 1124 Columbia St., Suite 200, Seattle, WA, 98104, USA
 SO Infection and Immunity, (June, 1999) Vol. 67, No. 6, pp. 2941-2950. print.
 CODEN: INFIBR. ISSN: 0019-9567.

DT Article
 LA English
 ED Entered STN: 24 Aug 1999
 Last Updated on STN: 24 Aug 1999

AB We have used expression screening of a genomic ***Mycobacterium*** tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of M. tuberculosis and ***Mycobacterium*** bovis BCG but not in other ***mycobacterial*** species tested. Immunoblot analysis demonstrated the presence of Mtb39A in M. tuberculosis lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to M.

tuberculosis CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from M. tuberculosis challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M. tuberculosis.

=> e reed steven/au

```
E1      4      REED STEVE I/AU
E2      1      REED STEVE M/AU
E3     15 --> REED STEVEN/AU
E4      1      REED STEVEN ANTHONY/AU
E5      1      REED STEVEN B/AU
E6      1      REED STEVEN C/AU
E7      1      REED STEVEN C SR/AU
E8      2      REED STEVEN F/AU
E9     435      REED STEVEN G/AU
E10    259      REED STEVEN I/AU
E11     1      REED STEVEN IRA/AU
E12     4      REED STEVEN J/AU
```

=> s e9 and mycobact?

```
L5      133 "REED STEVEN G"/AU AND MYCOBACT?
```

=> dup rem 15

PROCESSING COMPLETED FOR L5

```
L6      107 DUP REM L5 (26 DUPLICATES REMOVED)
```

=> s l6 and ((mtb39)or(mtb32a)or(mtb59f)or(mtb72f)or(mtb72fmutsa))

```
L7      9 L6 AND ((MTB39) OR(MTB32A) OR(MTB59F) OR(MTB72F) OR(MTB72FMUTSA
    ))
```

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

```
L7  ANSWER 1 OF 9 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN  1999:379686 BIOSIS
DN  PREV199900379686
TI  Cloning, expression, and immunological evaluation of two putative secreted
    serine protease antigens of ***Mycobacterium*** tuberculosis.
AU  Skeiky, Yasir A. W. [Reprint author]; Lodes, Michael J.; Guderian, Jeffrey
    A.; Mohamath, Raodoh; Bement, Teresa; Alderson, Mark R.; ***Reed, Steven***
    *** G.***
CS  Corixa Corporation, 1124 Columbia St., Seattle, WA, 98104, USA
SO  Infection and Immunity, (Aug., 1999) Vol. 67, No. 8, pp. 3998-4007. print.
    CODEN: INFIBR. ISSN: 0019-9567.
DT  Article
LA  English
OS  Genbank-S47170; Genbank-U15180
ED  Entered STN: 13 Sep 1999
    Last Updated on STN: 13 Sep 1999
AB  Culture filtrate proteins (CFP) of ***Mycobacterium*** tuberculosis
    have been shown to contain immunogenic components that elicit at least
    partial protective immunity against ***Mycobacterium*** infection. To
    clone genes encoding some of the immunogenic proteins, we made a
    high-titer rabbit anti-CFP serum and used it to screen an M. tuberculosis
    genomic expression library in Escherichia coli. In this paper, we
    describe the molecular cloning of two new protein components of CFP and
    identified them as members of the serine protease gene family. Their open
    reading frames contain N-terminal hydrophobic secretory signals consistent
    with their detection in CFP. The predicted molecular masses of the
    mature, fully processed forms of both antigens are approx 32 kDa, in
    agreement with their observed sizes on immunoblots of CFP probed with
    polyclonal rabbit antisera made to the recombinant proteins. Thus, these
    proteins have been designated ***MTB32A*** and MTB32B. Interestingly,
    and despite 66% amino acid sequence homology between the two proteins,
    polyclonal rabbit antisera made to each of the recombinant proteins were
```


found to be specific for the respective immunizing antigens. The recombinant proteins were also evaluated in in vitro assays with donor peripheral blood mononuclear cells (PBMC) from healthy purified protein derivative (PPD)-positive individuals of diverse ethnic backgrounds.

MTB32A but not MTB32B stimulated PBMC from healthy PPD-positive donors but not from PPD-negative donors to proliferate and secrete gamma interferon. ***MTB32A*** is encoded by a single-copy gene which is present in both virulent and avirulent strains of the *M. tuberculosis* complex and the BCG strain of ***Mycobacterium*** bovis but absent in the environmental ***mycobacterial*** species tested. In addition, nucleotide sequence comparison of ***mtb32a*** of the avirulent H37Ra strain and the virulent Erdman strain, as well as with the corresponding sequences (identified in the databases) of strain H37Rv and the clinical isolate CSU93, revealed 100% identity. ***MTB32A***, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during ***Mycobacterium*** spp. infection is discussed.

L7 ANSWER 2 OF 9 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:327567 BIOSIS
DN PREV199900327567
TI Molecular characterization and human T-Cell responses to a member of a novel ***Mycobacterium*** tuberculosis ***mtb39*** gene family.
AU Dillon, Davin C. [Reprint author]; Alderson, Mark R.; Day, Craig H.; Lewinson, David M.; Coler, Rhea; Bement, Teresa; Campos-Neto, Antonio; Skeiky, Y. A. W.; Orme, Ian M.; Roberts, Alan; Steen, Sean; Dalemans, Wilfried; Badaro, Roberto; ***Reed, Steven G.***
CS Corixa Corporation, 1124 Columbia St., Suite 200, Seattle, WA, 98104, USA
SO Infection and Immunity, (June, 1999) Vol. 67, No. 6, pp. 2941-2950. print. CODEN: INFIBR. ISSN: 0019-9567.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999
AB We have used expression screening of a genomic ***Mycobacterium*** tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of *M. tuberculosis* and ***Mycobacterium*** bovis BCG but not in other ***mycobacterial*** species tested. Immunoblot analysis demonstrated the presence of Mtb39A in *M. tuberculosis* lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to *M. tuberculosis* CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from *M. tuberculosis* challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for *M. tuberculosis*.

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:462305 CAPLUS
TI Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, ***Mtb72F***, Delivered as Naked DNA or Recombinant Protein
AU Skeiky, Yasir A. W.; Alderson, Mark R.; Ovendale, Pamela J.; Guderian, Jeffrey A.; Brandt, Lise; Dillon, Davin C.; Campos-Neto, Antonio; Lobet, Yves; Dalemans, Wilfried; Orme, Ian M.; ***Reed, Steven G.***
CS Corixa Corp., Seattle, WA, 98104, USA
SO Journal of Immunology (2004), 172(12), 7618-7628
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal

LA English

AB Key Ags of ***Mycobacterium*** tuberculosis initially identified in the context of host responses in healthy purified protein deriv.-pos. donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, ***Mtb72F***, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C- ***Mtb39*** -Mtb32N. Immunization of C57BL/6 mice with ***Mtb72F*** DNA resulted in the generation of IFN-.gamma. responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with ***Mtb72F*** protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-.gamma. response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of ***Mtb72F*** protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-.gamma. and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of ***Mtb72F*** immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with ***Mtb72F***, delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 yr) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization. ***Mtb72F*** in AS02A formulation is currently in phase I clin. trial, making it the first recombinant tuberculosis vaccine to be tested in humans.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:526194 CAPLUS

DN 135:117956

TI Nucleic acids and polypeptides for the therapy and diagnosis of human prostate cancer

IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; ***Reed, Steven G.***; Kalos, Michael D.; Fanger, Gary Richard; Day, Craig H.; Retter, Marc W.; Stolk, John A.; Skeiky, Yasir A. W.; Wang, Aijun; Meagher, Madeleine Joy

PA Corixa Corporation, USA

SO PCT Int. Appl., 543 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051633	A2	20010719	WO 2001-US1574	20010116
WO 2001051633	A3	20020620		
WO 2001051633	C2	20021031		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1261708	A2	20021204	EP 2001-906582	20010116
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001007643	A	20030610	BR 2001-7643	20010116
JP 2003528591	T2	20030930	JP 2001-551207	20010116
NO 2002003402	A	20020829	NO 2002-3402	20020715
PRAI US 2000-483672	A	20000114		
WO 2001-US1574	W	20010116		

AB Compns. and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Several hundred prostate-specific polynucleotides (and their encoded polypeptides) are isolated from human prostate tumor cDNA libraries by cDNA library subtraction, PCR-based subtraction, electronic subtraction, and microarray anal. Illustrative

comps. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that express such polypeptides, and T cells that are specific for cells expressing such polypeptides. Recombinant systems are described for the expression of such prostate-specific polypeptides in Escherichia coli, baculovirus, Saccharomyces cerevisiae, and mammalian cells. The disclosed comps. are useful, for example, in the diagnosis, prevention, and/or treatment of diseases, particularly prostate cancer.

L7 ANSWER 5 OF 9 USPATFULL on STN
AN 2004:44240 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN ***Reed, Steven G.***, Bellevue, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2004033230 A1 20040219
AI US 2003-453919 A1 20030602 (10)
RLI Continuation of Ser. No. US 2001-778381, filed on 6 Feb 2001, PENDING
Continuation-in-part of Ser. No. US 2000-687507, filed on 12 Oct 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-602877, filed on 22
Jun 2000, GRANTED, Pat. No. US 6432707 Continuation-in-part of Ser. No.
US 1999-346327, filed on 2 Jul 1999, GRANTED, Pat. No. US 6410507
Continuation-in-part of Ser. No. US 1999-288950, filed on 9 Apr 1999,
ABANDONED Continuation-in-part of Ser. No. US 1999-248178, filed on 9
Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-118627,
filed on 17 Jul 1998, GRANTED, Pat. No. US 6379951 Continuation-in-part
of Ser. No. US 1997-998253, filed on 24 Dec 1997, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L7 ANSWER 6 OF 9 USPATFULL on STN
AN 2003:213274 USPATFULL
TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and
their uses
IN ***Reed, Steven G.***, Bellevue, WA, UNITED STATES
Skeiky, Yasir A., Bellevue, WA, UNITED STATES
Dillon, Davin C., Redmond, WA, UNITED STATES
Alderson, Mark, Bainbridge, WA, UNITED STATES
Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003147911 A1 20030807
AI US 2003-359460 A1 20030205 (10)
RLI Continuation of Ser. No. US 1999-287849, filed on 7 Apr 1999, ABANDONED
Continuation-in-part of Ser. No. US 1998-223040, filed on 30 Dec 1998,
GRANTED, Pat. No. US 6544522 Continuation-in-part of Ser. No. US
1998-56556, filed on 7 Apr 1998, GRANTED, Pat. No. US 6350456
Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998,
ABANDONED Continuation-in-part of Ser. No. US 1997-942578, filed on 1
Oct 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-818112,
filed on 13 Mar 1997, GRANTED, Pat. No. US 6290969
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH

FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 68 Drawing Page(s)
LN.CNT 3971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins containing at least two
Mycobacterium tuberculosis antigens. In particular, it relates
to bi-fusion proteins which contain two individual M. tuberculosis
antigens, tri-fusion proteins which contain three M. tuberculosis
antigens, tetra-fusion proteins which contain four M. tuberculosis
antigens, and penta-fusion proteins which contain five M. tuberculosis
antigens, and methods for their use in the diagnosis, treatment and
prevention of tuberculosis infection.

L7 ANSWER 7 OF 9 USPATFULL on STN

AN 2002:295321 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Fridakis, Tony N., Sarasota, FL, UNITED STATES

Reed, Steven G., Bellevue, WA, UNITED STATES

Smith, John M., Columbia Heights, MN, UNITED STATES

Misher, Lynda E., Seattle, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Day, Craig H., Shoreline, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES

Deng, Ta, Edmonds, WA, UNITED STATES

PI US 2002165371 A1 20021107

AI US 2001-924400 A1 20010807 (9)

RLI Continuation-in-part of Ser. No. US 2001-810936, filed on 16 Mar 2001,
PENDING Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct
2000, PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on
8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505,
filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US
2000-534825, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser.
No. US 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part
of Ser. No. US 1999-289198, filed on 9 Apr 1999, PENDING
Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998,
GRANTED, Pat. No. US 6344550 Continuation-in-part of Ser. No. US
1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054
Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997,
ABANDONED A 371 of International Ser. No. WO 1997-US485, filed on 10 Jan
1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-585392, filed on
11 Jan 1996, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 22 Drawing Page(s)

LN.CNT 8977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L7 ANSWER 8 OF 9 USPATFULL on STN

AN 2002:205876 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN ***Reed, Steven G.***, Bellevue, WA, UNITED STATES

Lodes, Michael J., Seattle, WA, UNITED STATES

Mohamath, Raodoh, Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES
 Benson, Darin R., Seattle, WA, UNITED STATES
 Indirias, Carol Yoseph, Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 Fling, Steven P., Bainbridge Island, WA, UNITED STATES
 Algate, Paul A., Issaquah, WA, UNITED STATES
 Elliott, Mark, Seattle, WA, UNITED STATES
 Mannion, Jane, Edmonds, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES

PI US 2002110563 A1 20020815
 AI US 2000-738973 A1 20001214 (9)
 RLI Continuation-in-part of Ser. No. US 2000-704512, filed on 1 Nov 2000,
 PENDING

DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5236
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.

I7 ANSWER 9 OF 9 USPATFULL on STN
 AN 2002:133434 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of breast cancer
 IN Frudakis, Tony N., Sarasota, FL, UNITED STATES
 Reed, Steven G., Bellevue, WA, UNITED STATES
 Smith, John M., Columbia Heights, MN, UNITED STATES
 Misher, Lynda E., Seattle, WA, UNITED STATES
 Dillon, Davin C., Issaquah, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Harlocker, Susan L., Seattle, WA, UNITED STATES
 Day, Craig H., Seattle, WA, UNITED STATES

PI US 2002068285 A1 20020606
 AI US 2001-810936 A1 20010316 (9)
 RLI Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on 8 Jun
 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505, filed on
 24 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-534825,
 filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US
 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part of Ser.
 No. US 1999-289198, filed on 9 Apr 1999, PENDING Continuation-in-part of
 Ser. No. US 1998-62451, filed on 17 Apr 1998, PENDING
 Continuation-in-part of Ser. No. US 1997-991789, filed on 11 Dec 1997,
 GRANTED, Pat. No. US 6225054 Continuation-in-part of Ser. No. US
 1997-838762, filed on 9 Apr 1997, ABANDONED Continuation-in-part of Ser.
 No. US 1996-700014, filed on 20 Aug 1996, ABANDONED Continuation-in-part
 of Ser. No. US 1996-585392, filed on 11 Jan 1996, ABANDONED

DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 22 Drawing Page(s)
 LN.CNT 8540
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly breast cancer, are disclosed. Illustrative compositions
 comprise one or more breast tumor polypeptides, immunogenic portions

thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

=> e alderson mark/au

```
E1      2      ALDERSON M S/AU
E2      1      ALDERSON M W/AU
E3     36 --> ALDERSON MARK/AU
E4      2      ALDERSON MARK L/AU
E5     128     ALDERSON MARK R/AU
E6      3      ALDERSON MARK RAYMOND/AU
E7      4      ALDERSON MARY KATHRYN/AU
E8      1      ALDERSON MAX/AU
E9      7      ALDERSON N/AU
E10     13     ALDERSON N A/AU
E11     10     ALDERSON N B/AU
E12     51     ALDERSON N E/AU
```

=> s e1-e6 and mycobact?

```
L8      56 ("ALDERSON M S"/AU OR "ALDERSON M W"/AU OR "ALDERSON MARK"/AU
OR "ALDERSON MARK L"/AU OR "ALDERSON MARK R"/AU OR "ALDERSON
MARK RAYMOND"/AU) AND MYCOBACT?
```

=> dup rem l8

PROCESSING COMPLETED FOR L8

```
L9      40 DUP REM L8 (16 DUPLICATES REMOVED)
```

=> s l9 and ((mtb39)or(mtb32a)or(mtb59f)or(mtb72f)or(mtb72fmutsa))

```
L10     6 L9 AND ((MTB39) OR (MTB32A) OR (MTB59F) OR (MTB72F) OR (MTB72FMUTSA
))
```

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

```
L10  ANSWER 1 OF 6 BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   1999:379686 BIOSIS
DN   PREV199900379686
TI   Cloning, expression, and immunological evaluation of two putative secreted
serine protease antigens of ***Mycobacterium*** tuberculosis.
AU   Skeiky, Yasir A. W. [Reprint author]; Lodes, Michael J.; Guderian, Jeffrey
A.; Mohamath, Raodoh; Bement, Teresa; ***Alderson, Mark R.*** ; Reed,
Steven G.
CS   Corixa Corporation, 1124 Columbia St., Seattle, WA, 98104, USA
SO   Infection and Immunity, (Aug., 1999) Vol. 67, No. 8, pp. 3998-4007. print.
CODEN: INFIBR. ISSN: 0019-9567.
DT   Article
LA   English
OS   Genbank-S47170; Genbank-U15180
ED   Entered STN: 13 Sep 1999
Last Updated on STN: 13 Sep 1999
AB   Culture filtrate proteins (CFP) of ***Mycobacterium*** tuberculosis
have been shown to contain immunogenic components that elicit at least
partial protective immunity against ***Mycobacterium*** infection. To
clone genes encoding some of the immunogenic proteins, we made a
high-titer rabbit anti-CFP serum and used it to screen an M. tuberculosis
genomic expression library in Escherichia coli. In this paper, we
describe the molecular cloning of two new protein components of CFP and
identified them as members of the serine protease gene family. Their open
reading frames contain N-terminal hydrophobic secretory signals consistent
with their detection in CFP. The predicted molecular masses of the
mature, fully processed forms of both antigens are apprx32 kDa, in
agreement with their observed sizes on immunoblots of CFP probed with
polyclonal rabbit antisera made to the recombinant proteins. Thus, these
proteins have been designated ***MTB32A*** and MTB32B. Interestingly,
and despite 66% amino acid sequence homology between the two proteins,
polyclonal rabbit antisera made to each of the recombinant proteins were
found to be specific for the respective immunizing antigens. The
recombinant proteins were also evaluated in in vitro assays with donor
```

peripheral blood mononuclear cells (PBMC) from healthy purified protein derivative (PPD)-positive individuals of diverse ethnic backgrounds.

MTB32A but not MTB32B stimulated PBMC from healthy PPD-positive donors but not from PPD-negative donors to proliferate and secrete gamma interferon. ***MTB32A*** is encoded by a single-copy gene which is present in both virulent and avirulent strains of the *M. tuberculosis* complex and the BCG strain of ***Mycobacterium*** bovis but absent in the environmental ***mycobacterial*** species tested. In addition, nucleotide sequence comparison of ***mtb32a*** of the avirulent H37Ra strain and the virulent Erdman strain, as well as with the corresponding sequences (identified in the databases) of strain H37Rv and the clinical isolate CSU93, revealed 100% identity. ***MTB32A***, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during ***Mycobacterium*** spp. infection is discussed.

L10 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AN 1999:327567 BIOSIS

DN PREV199900327567

TI Molecular characterization and human T-Cell responses to a member of a novel ***Mycobacterium*** tuberculosis ***mtb39*** gene family.

AU Dillon, Davin C. [Reprint author]; ***Alderson, Mark R.*** ; Day, Craig H.; Lewinsohn, David M.; Coler, Rhea; Bement, Teresa; Campos-Neto, Antonio; Skeiky, Y. A. W.; Orme, Ian M.; Roberts, Alan; Steen, Sean; Dalemans, Wilfried; Badaro, Roberto; Reed, Steven G.

CS Corixa Corporation, 1124 Columbia St., Suite 200, Seattle, WA, 98104, USA

SO Infection and Immunity, (June, 1999) Vol. 67, No. 6, pp. 2941-2950. print. CODEN: INFIBR. ISSN: 0019-9567.

DT Article

LA English

ED Entered STN: 24 Aug 1999

Last Updated on STN: 24 Aug 1999

AB We have used expression screening of a genomic ***Mycobacterium*** tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of *M. tuberculosis* and ***Mycobacterium*** bovis BCG but not in other ***mycobacterial*** species tested. Immunoblot analysis demonstrated the presence of Mtb39a in *M. tuberculosis* lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39a protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to *M. tuberculosis* CFP. Purified recombinant Mtb39a elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from *M. tuberculosis* challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for *M. tuberculosis*.

L10 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:462305 CAPLUS

TI Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, ***Mtb72F***, Delivered as Naked DNA or Recombinant Protein

AU Skeiky, Yasir A. W.; ***Alderson, Mark R.*** ; Ovendale, Pamela J.; Guderian, Jeffrey A.; Brandt, Lise; Dillon, Davin C.; Campos-Neto, Antonio; Lobet, Yves; Dalemans, Wilfried; Orme, Ian M.; Reed, Steven G.

CS Corixa Corp., Seattle, WA, 98104, USA

SO Journal of Immunology (2004), 172(12), 7618-7628

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

AB Key Ags of ***Mycobacterium*** tuberculosis initially identified in

the context of host responses in healthy purified protein deriv.-pos. donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, ***Mtb72F***, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C- ***Mtb39*** -Mtb32N. Immunization of C57BL/6 mice with ***Mtb72F*** DNA resulted in the generation of IFN-.gamma. responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with ***Mtb72F*** protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-.gamma. response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of ***Mtb72F*** protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-.gamma. and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of ***Mtb72F*** immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with ***Mtb72F***, delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 yr) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization. ***Mtb72F*** in AS02A formulation is currently in phase I clin. trial, making it the first recombinant tuberculosis vaccine to be tested in humans.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:372587 CAPLUS
DN 140:390287
TI Construction of fusion proteins of ***mycobacterium*** tuberculosis antigens and use as vaccines
IN Skeiky, Yasir; Reed, Steven; ***Alderson, Mark***
PA USA
SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 597,796.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004086523	A1	20040506	US 2001-886349	20010620
PRAI	US 2000-597796	A2	20000620		
	US 2001-265737P	P	20010201		

AB The present invention relates to compns. and fusion proteins contg. at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compns. and fusion proteins. The compns. of the invention increase serol. sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L10 ANSWER 5 OF 6 USPATFULL on STN
AN 2004:18375 USPATFULL
TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and their uses
IN Skeiky, Yasir, Bellevue, WA, UNITED STATES
Alderson, Mark, Bainbridge Island, WA, UNITED STATES
Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES
PI US 2004013677 A1 20040122
AI US 2003-359459 A1 20030205 (10)
RLI Continuation of Ser. No. US 1998-223040, filed on 30 Dec 1998, GRANTED, Pat. No. US 6544522
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 1244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins of
Mycobacterium tuberculosis antigens. In particular, it relates
to two fusion proteins, each of which contains three individual M.
tuberculosis antigens, and a fusion protein of two M. tuberculosis
antigens, their coding sequences, and methods for their use in the
treatment and prevention of tuberculosis.

L10 ANSWER 6 OF 6 USPATFULL on STN

AN 2003:213274 USPATFULL

TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and
their uses

IN Reed, Steven G., Bellevue, WA, UNITED STATES
Skeiky, Yasir A., Bellevue, WA, UNITED STATES
Dillon, Davin C., Redmond, WA, UNITED STATES

Alderson, Mark, Bainbridge, WA, UNITED STATES

PA Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES
Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003147911 A1 20030807

AI US 2003-359460 A1 20030205 (10)

RLI Continuation of Ser. No. US 1999-287849, filed on 7 Apr 1999, ABANDONED
Continuation-in-part of Ser. No. US 1998-223040, filed on 30 Dec 1998,
GRANTED, Pat. No. US 6544522 Continuation-in-part of Ser. No. US
1998-56556, filed on 7 Apr 1998, GRANTED, Pat. No. US 6350456
Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998,
ABANDONED Continuation-in-part of Ser. No. US 1997-942578, filed on 1
Oct 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-818112,
filed on 13 Mar 1997, GRANTED, Pat. No. US 6290969

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 68 Drawing Page(s)

LN.CNT 3971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins containing at least two
Mycobacterium tuberculosis antigens. In particular, it relates
to bi-fusion proteins which contain two individual M. tuberculosis
antigens, tri-fusion proteins which contain three M. tuberculosis
antigens, tetra-fusion proteins which contain four M. tuberculosis
antigens, and penta-fusion proteins which contain five M. tuberculosis
antigens, and methods for their use in the diagnosis, treatment and
prevention of tuberculosis infection.

=> s mycobact? and ((mtb39)or(mtb32a)or(mtb59f)or(mtb72f)or(mtb72fmutsa))

L11 160 MYCOBACT? AND ((MTB39) OR(MTB32A) OR(MTB59F) OR(MTB72F) OR(MTB72
FMUTSA))

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 135 DUP REM L11 (25 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 135 ANSWERS - CONTINUE? Y/(N):y

L12 ANSWER 1 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

AN 2004:372587 CAPLUS

DN 140:390287

TI Construction of fusion proteins of ***mycobacterium*** tuberculosis
antigens and use as vaccines

IN Skeiky, Yasir; Reed, Steven; Alderson, Mark

PA USA

SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 597,796.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI US 2004086523 A1 20040506 US 2001-886349 20010620
 PRAI US 2000-597796 A2 20000620
 US 2001-265737P P 20010201

AB The present invention relates to compns. and fusion proteins contg. at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compns. and fusion proteins. The compns. of the invention increase serol. sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L12 ANSWER 2 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

AN 2004:403055 CAPLUS

DN 140:405473

TI Lung tumor proteins, polynucleotides and antibodies for lung cancer therapy and diagnosis

IN Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Henderson, Robert A.; McNeill, Patricia D.

PA Corixa Corporation, USA

SO U.S., 230 pp., Cont.-in-part of U.S. 6,531,315.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 19

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6737514	B1	20040518	US 2000-630940	20000802
	US 2003119763	A1	20030626	US 1999-466396	19991217
	US 6696247	B2	20040224		
	US 6706262	B1	20040316	US 1999-476496	19991230
	US 6482597	B1	20021119	US 2000-480884	20000110
	US 6518256	B1	20030211	US 2000-542615	20000404
	US 6531315	B1	20030311	US 2000-606421	20000628
	US 6426072	B1	20020730	US 2000-643597	20000821
	US 2002052329	A1	20020502	US 2000-735705	20001212
	WO 2002000174	A2	20020103	WO 2001-US21065	20010628
	WO 2002000174	A3	20030410		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001073149	A5	20020108	AU 2001-73149	20010628
	US 2002147143	A1	20021010	US 2001-897778	20010628
	EP 1319069	A2	20030618	EP 2001-952390	20010628
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513615	T2	20040513	JP 2002-504957	20010628
	US 2003064947	A1	20030403	US 2001-7700	20011130
	US 2003138438	A1	20030724	US 2002-117982	20020405
	US 2003236209	A1	20031225	US 2002-313986	20021204
PRAI	US 1999-285479	A2	19990402		
	US 1999-466396	A2	19991217		
	US 1999-476496	A2	19991230		
	US 2000-480884	A2	20000110		
	US 2000-510376	A2	20000222		
	US 2000-542615	A2	20000404		
	US 2000-606421	A2	20000628		
	US 1998-40802	B2	19980318		
	US 1998-123912	A2	19980727		
	US 1998-221107	A1	19981222		
	WO 1999-US5798	A1	19990317		
	US 2000-630940	A2	20000802		
	US 2000-643597	A2	20000821		
	US 2000-662786	A2	20000915		
	US 2000-685696	A2	20001009		
	US 2000-735705	A	20001212		

US 2001-850716 A 20010507
US 2001-897778 A2 20010628
WO 2001-US21065 W 20010628
US 2001-7700 A2 20011130
US 2002-117982 A2 20020405

AB Compsns. and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compsns. may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. The lung tumor proteins are identified and characterized from cDNA libraries of human lung squamous cell carcinoma and human lung adenocarcinoma. Alternatively, a therapeutic compn. may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 135 USPATFULL on STN

AN 2004:133363 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Dillon, Davin C., Issaquah, WA, UNITED STATES

Day, Craig H., Shoreline, WA, UNITED STATES

Jiang, Yuqiu, San Diego, CA, UNITED STATES

Houghton, Raymond L., Bothell, WA, UNITED STATES

Mitcham, Jennifer L., Redmond, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2004101899 A1 20040527

AI US 2003-714389 A1 20031113 (10)

RLI Division of Ser. No. US 2001-778320, filed on 6 Feb 2001, PENDING
Continuation-in-part of Ser. No. US 2000-571025, filed on 15 May 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-545068, filed on 7
Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-523586,
filed on 10 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-510662, filed on 22 Feb 2000, ABANDONED Continuation-in-part of
Ser. No. US 1999-451651, filed on 30 Nov 1999, GRANTED, Pat. No. US
6489101

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 4 OF 135 USPATFULL on STN

AN 2004:95560 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Frudakis, Tony N., Sarasota, FL, UNITED STATES

Reed, Steven G., Bellevue, WA, UNITED STATES

Smith, John M., Columbia Heights, MN, UNITED STATES

Misher, Lynda E., Seattle, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Day, Craig H., Shoreline, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES
Deng, Ta, Edmonds, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)
PI US 2004073016 A1 20040415
AI US 2002-79137 A1 20020220 (10)
RLI Continuation-in-part of Ser. No. US 2001-924400, filed on 7 Aug 2001,
PENDING Continuation-in-part of Ser. No. US 2001-810936, filed on 16 Mar
2001, PENDING Continuation-in-part of Ser. No. US 2000-699295, filed on
26 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-590583,
filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-577505, filed on 24 May 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-534825, filed on 23 Mar 2000, PENDING
Continuation-in-part of Ser. No. US 1999-429755, filed on 28 Oct 1999,
GRANTED, Pat. No. US 6656480 Continuation-in-part of Ser. No. US
1999-289198, filed on 9 Apr 1999, GRANTED, Pat. No. US 6586570
Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998,
GRANTED, Pat. No. US 6344550 Continuation-in-part of Ser. No. US
1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054
Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997,
ABANDONED Continuation-in-part of Ser. No. US 1996-700014, filed on 20
Aug 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-585392,
filed on 11 Jan 1996, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 10374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 5 OF 135 USPATFULL on STN

AN 2004:70914 USPATFULL
TI Cripto tumour polypeptide
IN Cassart, Jean-Pol, Rixensart, BELGIUM
Coche, Thierry, Rixensart, BELGIUM
Palmantier, Remi M, Rixensart, BELGIUM
Bassols, Carlota Vinals Y De, Rixensart, BELGIUM
PI US 2004054142 A1 20040318
AI US 2003-362597 A1 20030804 (10)
WO 2001-EP9646 20010820
PRAI GB 2000-20953 20000824
DT Utility
FS APPLICATION
LREP SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US,
UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4152

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly lung, colon, colorectal and breast cancer, are disclosed.
Illustrative compositions comprise one or more Cripto tumor
polypeptides, immunogenic portions thereof, polynucleotides that encode
such polypeptides, antigen presenting cell that expresses such
polypeptides, and T cells that are specific for cells expressing such
polypeptides. The disclosed compositions are useful, for example, in the
diagnosis, prevention and/or treatment of diseases, particularly lung,
colon, colorectal and breast cancer.

L12 ANSWER 6 OF 135 USPATFULL on STN

AN 2004:57924 USPATFULL
TI Compositions and methods for the therapy and diagnosis of inflammatory
bowel disease
IN Hersberg, Robert M., UNITED STATES
Hosken, Nancy Ann, UNITED STATES
Lodes, Michael J., UNITED STATES
Mohamath, Raodoh, UNITED STATES
PI US 2004043931 A1 20040304
AI US 2003-449857 A1 20030530 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US40422, filed on 16 Dec 2002,
PENDING
PRAI US 2002-426835P 20021115 (60)
US 2002-396242P 20020716 (60)
US 2001-341830P 20011217 (60)
DT Utility
FS APPLICATION
LREP CORIXA CORPORATION, 1124 COLUMBIA STREET, SUITE 200, SEATTLE, WA, 98104
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 6314

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of Inflammatory
Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis,
are disclosed. Illustrative compositions comprise one or more bacterial
polypeptides, immunogenic portions thereof, polynucleotides that encode
such polypeptides, antigen presenting cell that expresses such
polypeptides, and T cells that are specific for cells expressing such
polypeptides. The disclosed compositions are useful, for example, in the
diagnosis, prevention and/or treatment of IBD.

L12 ANSWER 7 OF 135 USPATFULL on STN

AN 2004:50415 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
King, Gordon E., Shoreline, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2004037842 A1 20040226
AI US 2002-97105 A1 20020313 (10)
RLI Continuation-in-part of Ser. No. US 2001-815343, filed on 22 Mar 2001,
ABANDONED
PRAI US 2000-191597P 20000324 (60)
US 2000-202024P 20000504 (60)
US 2000-202189P 20000505 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly colon cancer, are disclosed. Illustrative compositions
comprise one or more colon tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 8 OF 135 USPATFULL on STN

AN 2004:44240 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Reed, Steven G., Bellevue, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2004033230 A1 20040219
AI US 2003-453919 A1 20030602 (10)
RLI Continuation of Ser. No. US 2001-778381, filed on 6 Feb 2001, PENDING
Continuation-in-part of Ser. No. US 2000-687507, filed on 12 Oct 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-602877, filed on 22
Jun 2000, GRANTED, Pat. No. US 6432707 Continuation-in-part of Ser. No.
US 1999-346327, filed on 2 Jul 1999, GRANTED, Pat. No. US 6410507
Continuation-in-part of Ser. No. US 1999-288950, filed on 9 Apr 1999,
ABANDONED Continuation-in-part of Ser. No. US 1999-248178, filed on 9
Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-118627,
filed on 17 Jul 1998, GRANTED, Pat. No. US 6379951 Continuation-in-part
of Ser. No. US 1997-998253, filed on 24 Dec 1997, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5762

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 9 OF 135 USPATFULL on STN

AN 2004:24366 USPATFULL
TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander, Vienna, AUSTRIA
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Jaya, Nomalie, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2004018204 A1 20040129
AI US 2003-427717 A1 20030430 (10)
RLI Continuation-in-part of Ser. No. US 2002-286333, filed on 30 Oct 2002,
PENDING Continuation-in-part of Ser. No. US 2002-244830, filed on 16 Sep
2002, PENDING Continuation-in-part of Ser. No. US 2002-195835, filed on
12 Jul 2002, PENDING Continuation-in-part of Ser. No. US 2002-125635,
filed on 16 Apr 2002, PENDING Continuation-in-part of Ser. No. US
2001-2603, filed on 30 Oct 2001, PENDING Continuation-in-part of Ser.
No. US 2001-938864, filed on 24 Aug 2001, PENDING
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 11326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as
leukemia and cancer, are disclosed. The compositions comprise one or
more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting
cell presenting a WT1 polypeptide, an antibody that specifically binds
to a WT1 polypeptide; or a T cell that specifically reacts with a WT1
polypeptide. Such compositions may be used, for example, for the
prevention and treatment of metastatic diseases.

L12 ANSWER 10 OF 135 USPATFULL on STN

AN 2004:18375 USPATFULL
TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and
their uses
IN Skeiky, Yasir, Bellevue, WA, UNITED STATES

Alderson, Mark, Bainbridge Island, WA, UNITED STATES
 Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES
 PI US 2004013677 A1 20040122
 AI US 2003-359459 A1 20030205 (10)
 RLI Continuation of Ser. No. US 1998-223040, filed on 30 Dec 1998, GRANTED,
 Pat. No. US 6544522
 DT Utility
 FS APPLICATION
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
 FLOOR, SAN FRANCISCO, CA, 94111-3834
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 21 Drawing Page(s)
 LN.CNT 1244
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to fusion proteins of
 Mycobacterium tuberculosis antigens. In particular, it relates
 to two fusion proteins, each of which contains three individual M.
 tuberculosis antigens, and a fusion protein of two M. tuberculosis
 antigens, their coding sequences, and methods for their use in the
 treatment and prevention of tuberculosis.

L12 ANSWER 11 OF 135 USPATFULL on STN
 AN 2004:13419 USPATFULL
 TI Microspheres and adjuvants for DNA vaccine delivery
 IN Johnson, Mark E., Bellevue, WA, UNITED STATES
 Mossman, Sally, Seattle, WA, UNITED STATES
 Cecil, Tricia, Bellevue, WA, UNITED STATES
 Evans, Lawrence, Seattle, WA, UNITED STATES
 PA Corixa Corporation (U.S. corporation)
 PI US 2004009941 A1 20040115
 AI US 2003-420482 A1 20030422 (10)
 RLI Division of Ser. No. US 2001-901829, filed on 9 Jul 2001, ABANDONED
 PRAI US 2000-216604P 20000707 (60)
 DT Utility
 FS APPLICATION
 LREP Attention of Karen S. Canady, Gates & Cooper LLP, Howard Hughes Center,
 6701 Center Drive West, Suite 1050, Los Angeles, CA, 90045
 CLMN Number of Claims: 53
 ECL Exemplary Claim: 1
 DRWN 17 Drawing Page(s)
 LN.CNT 1362
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A nucleic acid delivery system that offers, in one system, a combination
 of high encapsulation efficiency, rapid release kinetics and
 preservation of DNA in supercoiled form is provided. The nucleic acid
 delivery system comprises nucleic acid molecules, such as
 deoxyribonucleic acid (DNA), encapsulated in biodegradable microspheres,
 and is particularly suited for delivery of DNA vaccines. The invention
 further provides a method for encapsulating nucleic acid molecules in
 microspheres. The invention additionally provides a composition
 comprising nucleic acid molecules encapsulated in microspheres produced
 by a method of the invention, and a method for delivering a nucleic acid
 molecule to a subject. The invention further provides an adjuvant for
 modulating the immunostimulatory efficacy of microspheres encapsulating
 nucleic acid molecules comprising an aminoalkyl glucosaminide
 4-phosphate (AGP). The invention also provides a method for modulating
 the immunostimulatory efficacy of microspheres encapsulating nucleic
 acid molecules.

L12 ANSWER 12 OF 135 USPATFULL on STN
 AN 2004:12666 USPATFULL
 TI Recombinant intracellular pathogen immunogenic compositions and methods
 for use
 IN Horwitz, Marcus A., Los Angeles, CA, UNITED STATES
 Harth, Gunter, Los Angeles, CA, UNITED STATES
 Tullius, Michael V., Encino, CA, UNITED STATES
 PI US 2004009184 A1 20040115
 AI US 2003-439611 A1 20030515 (10)
 RLI Continuation-in-part of Ser. No. US 2002-261981, filed on 30 Sep 2002,
 ABANDONED Continuation-in-part of Ser. No. US 2000-550468, filed on 17

Apr 2000, GRANTED, Pat. No. US 6471967

DT Utility

FS APPLICATION

LREP OPPENHEIMER WOLFF & DONNELLY LLP, 840 NEWPORT CENTER DRIVE, SUITE 700,
NEWPORT BEACH, CA, 92660

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 2450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant ***Mycobacteria*** expressing the major extracellular non-fusion proteins of ***Mycobacteria*** and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.

L12 ANSWER 13 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3

AN 2004:462305 CAPLUS

TI Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, ***Mtb72F*** ,
Delivered as Naked DNA or Recombinant Protein

AU Skeiky, Yasir A. W.; Alderson, Mark R.; Owendale, Pamela J.; Guderian, Jeffrey A.; Brandt, Lise; Dillon, Davin C.; Campos-Neto, Antonio; Lobet, Yves; Dalemans, Wilfried; Orme, Ian M.; Reed, Steven G.

CS Corixa Corp., Seattle, WA, 98104, USA

SO Journal of Immunology (2004), 172(12), 7618-7628

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

AB Key Ags of ***Mycobacterium*** tuberculosis initially identified in the context of host responses in healthy purified protein deriv.-pos. donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, ***Mtb72F*** , codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C- ***Mtb39*** -Mtb32N. Immunization of C57BL/6 mice with ***Mtb72F*** DNA resulted in the generation of IFN-.gamma. responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with ***Mtb72F*** protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-.gamma. response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of ***Mtb72F*** protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-.gamma. and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of ***Mtb72F*** immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with ***Mtb72F*** , delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 yr) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization. ***Mtb72F*** in AS02A formulation is currently in phase I clin. trial, making it the first recombinant tuberculosis vaccine to be tested in humans.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4

AN 2003:390752 CAPLUS

DN 138:396181

TI Immunoreactive nucleic acids and proteins for treatment and diagnosis of chlamydial infection

IN Skeiky, Yasir A. W.; Scholler, John

PA Corixa Corporation, USA

SO U.S., 233 pp., Cont.-in-part of U.S. 6,432,916.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6565856	B1	20030520	US 2000-598419	20000620
US 6166177	A	20001226	US 1998-208277	19981208
US 6447779	B1	20020910	US 1999-288594	19990408
US 6555115	B1	20030429	US 1999-410568	19991001
US 6432916	B1	20020813	US 2000-556877	20000419
US 6448234	B1	20020910	US 2000-620412	20000720
WO 2001040474	A2	20010607	WO 2000-US32919	20001204
WO 2001040474	A3	20020307		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1238084	A2	20020911	EP 2000-980969	20001204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003515343	T2	20030507	JP 2001-542539	20001204
BR 2000016066	A	20030610	BR 2000-16066	20001204
NO 2002002592	A	20020719	NO 2002-2592	20020531
PRAI US 1998-208277	A2	19981208		
US 1999-288594	A2	19990408		
US 1999-410568	A2	19991001		
US 1999-426571	A1	19991022		
US 1999-454684	A2	19991203		
US 2000-556877	A2	20000419		
US 2000-598419	A2	20000620		
WO 2000-US32919	W	20001204		

AB Comps. and methods for the diagnosis and treatment of Chlamydial infection are disclosed. Chlamydia antigens of the present invention were isolated by expression cloning of genomic DNA libraries of Chlamydia trachomatis LGV II and Chlamydia pneumonia strain TWAR, and were shown to induce PBMC proliferation and interferon- γ prodn. in immunoreactive T cell lines. The comps. provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. In particular, the invention provides the C. trachomatis polymorphic membrane protein PmpD. Pharmaceutical comps. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Various Pmp/Ral2 fusion constructs are also provided, where Ral2 comprises residues 192-323 of the ***Mycobacterium*** tuberculosis ***MTB32A*** serine proteinase. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:678617 CAPLUS

DN 139:212869

TI Fusion proteins of ***Mycobacterium*** tuberculosis and use as vaccine for antituberculosis infection

IN Skeiky, Yasir; Guderian, Jeff; Reed, Steven

PA Corixa Corporation, USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003070187	A2	20030828	WO 2003-US4903	20030218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG

US 2003235593 A1 20031225 US 2003-369983 20030218

PRAI US 2002-357351P P 20020215

AB The present invention relates to compns. and fusion proteins contg. at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compns. and fusion proteins. The compns. of the invention increase serol. sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L12 ANSWER 16 OF 135 USPATFULL on STN

AN 2003:335331 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Foy, Teresa M., Federal Way, WA, UNITED STATES

McNabb, Andria, Renton, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Reed, Steven G., Bellevue, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003236209 A1 20031225

AI US 2002-313986 A1 20021204 (10)

RLI Continuation-in-part of Ser. No. US 2002-117982, filed on 5 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-7700, filed on 30 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000, GRANTED, Pat. No. US 6426072 Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, GRANTED, Pat. No. US 6531315 Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, GRANTED, Pat. No. US 6518256 Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, GRANTED, Pat. No. US 6482597 Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 17 OF 135 USPATFULL on STN
AN 2003:334717 USPATFULL
TI Fusion proteins of ***Mycobacterium*** tuberculosis
IN Skeiky, Yasir, Bellevue, WA, UNITED STATES
Guderian, Jeff, Lynwood, WA, UNITED STATES
Reed, Steven, Bellevue, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003235593 A1 20031225
AI US 2003-369983 A1 20030218 (10)
PRAI US 2002-357351P 20020215 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 85
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 2856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and fusion proteins containing at least two ***Mycobacterium*** sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

L12 ANSWER 18 OF 135 USPATFULL on STN
AN 2003:334682 USPATFULL
TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
Cheever, Martin A., Mercer Island, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003235557 A1 20031225
AI US 2002-244830 A1 20020916 (10)
RLI Continuation-in-part of Ser. No. US 2002-195835, filed on 12 Jul 2002, PENDING Continuation-in-part of Ser. No. US 2002-125635, filed on 16 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-2603, filed on 30 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-938864, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-785019, filed on 15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 9964

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 19 OF 135 USPATFULL on STN
AN 2003:329845 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Fanger, Gary R., Mill Creek, WA, UNITED STATES
Fling, Steven P., Bainbridge Island, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003232056 A1 20031218
AI US 2003-369186 A1 20030214 (10)

RLI Continuation-in-part of Ser. No. US 2003-361811, filed on 5 Feb 2003,
PENDING Continuation-in-part of Ser. No. US 2002-212677, filed on 2 Aug
2002, PENDING Continuation-in-part of Ser. No. US 2001-970966, filed on
2 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-825294,
filed on 3 Apr 2001, PENDING Continuation-in-part of Ser. No. US
2000-713550, filed on 14 Nov 2000, GRANTED, Pat. No. US 6617109
Continuation-in-part of Ser. No. US 2000-656668, filed on 7 Sep 2000,
PENDING Continuation-in-part of Ser. No. US 2000-640173, filed on 15 Aug
2000, GRANTED, Pat. No. US 6613515 Continuation-in-part of Ser. No. US
2000-561778, filed on 1 May 2000, ABANDONED Continuation-in-part of Ser.
No. US 1999-394374, filed on 10 Sep 1999, ABANDONED

DT Utility
FS APPLICATION
LREP CORIXA CORPORATION, 1124 COLUMBIA STREET, SUITE 200, SEATTLE, WA, 98104
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 20 OF 135 USPATFULL on STN

AN 2003:324306 USPATFULL
TI Compositions and methods for viral delivery
IN Mossman, Sally, Seattle, WA, UNITED STATES
Evans, Lawrence, Seattle, WA, UNITED STATES
Swanson, Ryan M., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)
PI US 2003228279 A1 20031211
AI US 2002-283484 A1 20021029 (10)
PRAI US 2002-369715P 20020403 (60)
US 2001-335512P 20011031 (60)

DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods comprising a recombinant virus and an
immunostimulant are provided for enhancing the immune response to a
polypeptide expressed from the recombinant virus. Preferably this is
done without also enhancing the neutralizing antibody response to the
recombinant virus. Illustrative compositions comprise an adenovirus and
an adjuvant such as, for example, monophosphoryl lipid A, an alkyl
glucosaminide phosphate, a saponin, or a combination thereof. The
disclosed compositions and methods are useful, for example, in the
treatment of diseases such as cancer or infectious disease.

L12 ANSWER 21 OF 135 USPATFULL on STN

AN 2003:306026 USPATFULL
TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Jaya, Nomalie, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003215458 A1 20031120
AI US 2002-286333 A1 20021030 (10)
RLI Continuation-in-part of Ser. No. US 2002-244830, filed on 16 Sep 2002,
PENDING Continuation-in-part of Ser. No. US 2002-195835, filed on 12 Jul
2002, PENDING Continuation-in-part of Ser. No. US 2002-125635, filed on
16 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-2603,

filed on 30 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-938864, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-785019, filed on 15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 43 Drawing Page(s)

LN.CNT 10799

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 22 OF 135 USPATFULL on STN

AN 2003:300287 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Henderson, Robert A., Edmonds, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

Johnson, Jeffrey C., Des Moines, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Durham, Margarita, Seattle, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Bangur, Chaitanya S., Seattle, WA, UNITED STATES

McNabb, Andria, Renton, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2003211510 A1 20031113

AI US 2002-283017 A1 20021028 (10)

RLI Continuation-in-part of Ser. No. US 2002-113872, filed on 28 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-17754, filed on 29 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-902941, filed on 10 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-849626, filed on 3 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-736457, filed on 13 Dec 2000, GRANTED, Pat. No. US 6509448 Continuation-in-part of Ser. No. US 2000-702705, filed on 30 Oct 2000, GRANTED, Pat. No. US 6504010 Continuation-in-part of Ser. No. US 2000-677419, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-671325, filed on 26 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-658824, filed on 8 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651563, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-614124, filed on 11 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-589184, filed on 5 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-560406, filed on 27 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-546259, filed on 10 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-533077, filed on 22 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-519642, filed on 6 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-476300, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466867, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-419356, filed on 15 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-346492, filed on 30 Jun 1999, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,

SEATTLE, WA, 98104-7092
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 23 OF 135 USPATFULL on STN

AN 2003:293906 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Fanger, Gary R., Mill Creek, WA, UNITED STATES
Fling, Steven P., Bainbridge Island, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003206918 A1 20031106
AI US 2003-361811 A1 20030205 (10)
RLI Continuation-in-part of Ser. No. US 2002-212677, filed on 2 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-970966, filed on 2 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-825294, filed on 3 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-713550, filed on 14 Nov 2000, GRANTED, Pat. No. US 6617109 Continuation-in-part of Ser. No. US 2000-656668, filed on 7 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640173, filed on 15 Aug 2000, GRANTED, Pat. No. US 6613515 Continuation-in-part of Ser. No. US 2000-561778, filed on 1 May 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-394374, filed on 10 Sep 1999, ABANDONED

DT Utility

FS APPLICATION

LREP CORIXA CORPORATION, 1124 COLUMBIA STREET, SUITE 200, SEATTLE, WA, 98104

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 24 OF 135 USPATFULL on STN

AN 2003:283116 USPATFULL
TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
IN Johnson, David A., Hamilton, MT, UNITED STATES
Sowell, C. Gregory, Mukilteo, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003199460 A1 20031023
AI US 2002-137730 A1 20020430 (10)
RLI Continuation-in-part of Ser. No. US 2002-43086, filed on 8 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2001-905160, filed on 12 Jul 2001, PENDING Continuation of Ser. No. US 1999-439839, filed on 12 Nov 1999, GRANTED, Pat. No. US 6303347 Continuation-in-part of Ser. No. US 1997-853826, filed on 8 May 1997, GRANTED, Pat. No. US 6113918

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5737

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

L12 ANSWER 25 OF 135 USPATFULL on STN

AN 2003:282281 USPATFULL

TI Compositions and methods for WT1 specific immunotherapy

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

Smithgall, Molly D., Seattle, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Cheever, Martin A., Mercer Island, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Sutherland, R. Alec, Bothell, WA, UNITED STATES

Mossman, Sally P., Seattle, WA, UNITED STATES

Evans, Lawrence S., Seattle, WA, UNITED STATES

Swanson, Ryan M., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2003198622 A1 20031023

AI US 2002-195835 A1 20020712 (10)

RLI Continuation-in-part of Ser. No. US 2002-125635, filed on 16 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-2603, filed on 30 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-938864, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-785019, filed on 15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 43 Drawing Page(s)

LN.CNT 9309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 26 OF 135 USPATFULL on STN

AN 2003:276739 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Bangur, Chaitanya S., Seattle, WA, UNITED STATES

Switzer, Ann, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003194764 A1 20031016

AI US 2002-116712 A1 20020404 (10)

PRAI US 2001-327511P 20011005 (60)

US 2001-282289P 20010405 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 12700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 27 OF 135 USPATFULL ON STN

AN 2003:264816 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003185830 A1 20031002

AI US 2002-294025 A1 20021112 (10)

RLI Continuation-in-part of Ser. No. US 2002-144678, filed on 9 May 2002, PENDING Continuation-in-part of Ser. No. US 2001-12896, filed on 10 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-759143, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505 Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999, GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US 1999-288946, filed on 9 Apr 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-232149, filed on 15 Jan 1999, GRANTED, Pat. No. US 6465611 Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb 1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US 1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562 Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25 Feb 1997, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 9180

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed

compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 28 OF 135 USPATFULL on STN

AN 2003:250508 USPATFULL

TI Heterologous fusion protein constructs comprising a Leishmania antigen

IN Skeiky, Yasir, Bellevue, WA, UNITED STATES

Brannon, Mark, Seattle, WA, UNITED STATES

Guderian, Jeffrey, Lynwood, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2003175294 A1 20030918

AI US 2002-98732 A1 20020313 (10)

PRAI US 2001-275837P 20010313 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 82

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 6952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant nucleic acid molecule encoding a fusion polypeptide, wherein the recombinant nucleic acid comprises a heterologous polynucleotide sequence encoding an antigen or an antigenic fragment, and a Leishmania polynucleotide sequence encoding a polypeptide or fragment thereof, wherein the Leishmania polynucleotide is selected from the group consisting of TSA polynucleotide, LeIF polynucleotide, M15 polynucleotide, and 6H polynucleotide. The invention also provides an expression cassette comprising the recombinant nucleic acid molecule, host cells comprising the expression cassette, compositions, fusion polypeptides, and methods of their use in diagnosis or in generating a protective immune response in hosts.

L12 ANSWER 29 OF 135 USPATFULL on STN

AN 2003:243846 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003170255 A1 20030911

AI US 2002-113872 A1 20020328 (10)

RLI Continuation-in-part of Ser. No. US 2001-17754, filed on 29 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-902941, filed on 10 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-849626, filed on 3 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-736457, filed on 13 Dec 2000, GRANTED, Pat. No. US 6509448 Continuation-in-part of Ser. No. US 2000-702705, filed on 30 Oct 2000, GRANTED, Pat. No. US 6504010 Continuation-in-part of Ser. No. US 2000-677419, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-671325, filed on 26 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-658824, filed on 8 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651563, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-614124, filed on 11 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-589184, filed on 5 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-560406, filed on 27 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-546259, filed on 10 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-533077, filed on 22 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-519642, filed on 6 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-476300, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466867, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-419356, filed on 15 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-346492, filed on 30 Jun 1999, ABANDONED

DT Utility

FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 8934
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 30 OF 135 USPATFULL on STN
 AN 2003:243837 USPATFULL
 TI Lipophilin complexes for use in cancer diagnosis and therapy
 IN Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Durham, Margarita, Seattle, WA, UNITED STATES
 Houghton, Raymond L., Bothell, WA, UNITED STATES
 Dillon, Davin C., Issaquah, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Persing, David H., Redmond, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
 PI US 2003170246 A1 20030911
 AI US 2002-96319 A1 20020312 (10)
 RLI Continuation-in-part of Ser. No. US 2001-905673, filed on 13 Jul 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-780842, filed on 8 Feb
 2001, ABANDONED
 PRAI US 2000-215735P 20000628 (60)
 US 2000-183495P 20000211 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 57
 ECL Exemplary Claim: 1
 DRWN 16 Drawing Page(s)
 LN.CNT 3906
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of breast,
 ovarian and prostate cancer are disclosed. Compositions may comprise one
 or more lipophilin fusion proteins, which comprise at least two
 different lipophilin-like polypeptides linked by a peptide bond. Such
 compositions may be used for the prevention and treatment of breast,
 ovarian and prostate cancer. Diagnostic methods based on detecting the
 presence of lipophilin complexes, or antibodies thereto, in a patient
 are also provided.

L12 ANSWER 31 OF 135 USPATFULL on STN
 AN 2003:237907 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN King, Gordon E., Shoreline, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003166064 A1 20030904
 AI US 2002-99926 A1 20020314 (10)
 RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul
 2001, PENDING
 PRAI US 2001-302051P 20010629 (60)
 US 2001-279763P 20010328 (60)
 US 2000-223283P 20000803 (60)
 DT Utility
 FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly colon cancer, are disclosed. Illustrative compositions
comprise one or more colon tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 32 OF 135 USPATFULL on STN

AN 2003:237865 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Houghton, Raymond L., Bothell, WA, UNITED STATES
Sleath, Paul R., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166022 A1 20030904
AI US 2002-124805 A1 20020415 (10)
RLI Continuation-in-part of Ser. No. US 2002-76622, filed on 13 Feb 2002,
PENDING Continuation-in-part of Ser. No. US 2001-7805, filed on 7 Dec
2001, PENDING Continuation-in-part of Ser. No. US 2001-834759, filed on
13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-620405,
filed on 20 Jul 2000, GRANTED, Pat. No. US 6528054 Continuation-in-part
of Ser. No. US 2000-604287, filed on 22 Jun 2000, GRANTED, Pat. No. US
6586572 Continuation-in-part of Ser. No. US 2000-590751, filed on 8 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-551621, filed on
17 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-433826,
filed on 3 Nov 1999, GRANTED, Pat. No. US 6579973 Continuation-in-part
of Ser. No. US 1999-389681, filed on 2 Sep 1999, GRANTED, Pat. No. US
6518237 Continuation-in-part of Ser. No. US 1999-339338, filed on 23 Jun
1999, GRANTED, Pat. No. US 6573368 Continuation-in-part of Ser. No. US
1999-285480, filed on 2 Apr 1999, GRANTED, Pat. No. US 6590076
Continuation-in-part of Ser. No. US 1998-222575, filed on 28 Dec 1998,
GRANTED, Pat. No. US 6387697

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)

LN.CNT 14461

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 33 OF 135 USPATFULL on STN

AN 2003:237663 USPATFULL
TI Compositions and methods for the diagnosis and treatment of herpes
simplex virus infection
IN Day, Craig H., Shoreline, WA, UNITED STATES
Hosken, Nancy A., Seattle, WA, UNITED STATES
Parsons, Joseph M., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003165820 A1 20030904
AI US 2002-237551 A1 20020906 (10)
RLI Continuation-in-part of Ser. No. US 2002-200562, filed on 19 Jul 2002,
PENDING Continuation-in-part of Ser. No. US 2002-121988, filed on 11 Apr

2002, PENDING Continuation-in-part of Ser. No. US 2001-894998, filed on 28 Jun 2001, PENDING

PRAI US 2001-277438P 20010320 (60)
US 2000-215458P 20000629 (60)
DT Utility
FS APPLICATION
LREP CORIXA CORPORATION, 1124 COLUMBIA STREET, SUITE 200, SEATTLE, WA, 98104
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.

L12 ANSWER 34 OF 135 USPATFULL on STN

AN 2003:237662 USPATFULL
TI Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
IN McGowan, Patrick, Seattle, WA, UNITED STATES
Hosken, Nancy A., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003165819 A1 20030904
AI US 2002-200562 A1 20020719 (10)
RLI Continuation-in-part of Ser. No. US 2002-121988, filed on 11 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-894998, filed on 28 Jun 2001, PENDING
PRAI US 2001-277438P 20010320 (60)
US 2000-215458P 20000629 (60)
DT Utility
FS APPLICATION
LREP CORIXA CORPORATION, 1124 COLUMBIA STREET, SUITE 200, SEATTLE, WA, 98104
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12864

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.

L12 ANSWER 35 OF 135 USPATFULL on STN

AN 2003:225278 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Hural, John, Bainbridge Island, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Houghton, Raymond L., Bothell, WA, UNITED STATES
 Vinals y de Bassols, Carlota, Rixensart, BELGIUM
 Foy, Teresa M., Federal Way, WA, UNITED STATES
 Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 Deng, Ta, Edmonds, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003157089 A1 20030821
 AI US 2002-144678 A1 20020509 (10)
 RLI Continuation-in-part of Ser. No. US 2001-12896, filed on 10 Dec 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun
 2001, PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on
 9 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-780669,
 filed on 9 Feb 2001, PENDING Continuation-in-part of Ser. No. US
 2001-759143, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser.
 No. US 2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part
 of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep
 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on
 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215,
 filed on 9 Aug 2000, PENDING Continuation-in-part of Ser. No. US
 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part
 of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar
 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed
 on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686,
 filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US
 1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505
 Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999,
 GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US
 1999-288946, filed on 9 Apr 1999, ABANDONED Continuation-in-part of Ser.
 No. US 1999-232149, filed on 15 Jan 1999, GRANTED, Pat. No. US 6465611
 Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998,
 PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul
 1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on
 25 Feb 1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser.
 No. US 1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
 Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,
 ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25
 Feb 1997, ABANDONED
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 10 Drawing Page(s)
 LN.CNT 8995
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly prostate cancer, are disclosed. Illustrative compositions
 comprise one or more prostate-specific polypeptides, immunogenic
 portions thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly prostate cancer.
 L12 ANSWER 36 OF 135 USPATFULL on STN
 AN 2003:213274 USPATFULL
 TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and
 their uses

IN Reed, Steven G., Bellevue, WA, UNITED STATES
 Skeiky, Yasir A., Bellevue, WA, UNITED STATES
 Dillon, Davin C., Redmond, WA, UNITED STATES
 Alderson, Mark, Bainbridge, WA, UNITED STATES
 Campos-Neto, Antonio, Bainbridge Island, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)
 PI US 2003147911 A1 20030807
 AI US 2003-359460 A1 20030205 (10)
 RLI Continuation of Ser. No. US 1999-287849, filed on 7 Apr 1999, ABANDONED
 Continuation-in-part of Ser. No. US 1998-223040, filed on 30 Dec 1998,
 GRANTED, Pat. No. US 6544522 Continuation-in-part of Ser. No. US
 1998-56556, filed on 7 Apr 1998, GRANTED, Pat. No. US 6350456
 Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998,
 ABANDONED Continuation-in-part of Ser. No. US 1997-942578, filed on 1
 Oct 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-818112,
 filed on 13 Mar 1997, GRANTED, Pat. No. US 6290969

DT Utility
 FS APPLICATION
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
 FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN 68 Drawing Page(s)
 LN.CNT 3971
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins containing at least two
 Mycobacterium tuberculosis antigens. In particular, it relates
 to bi-fusion proteins which contain two individual M. tuberculosis
 antigens, tri-fusion proteins which contain three M. tuberculosis
 antigens, tetra-fusion proteins which contain four M. tuberculosis
 antigens, and penta-fusion proteins which contain five M. tuberculosis
 antigens, and methods for their use in the diagnosis, treatment and
 prevention of tuberculosis infection.

L12 ANSWER 37 OF 135 USPATFULL on STN
 AN 2003:208133 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of ovarian cancer
 IN Algate, Paul A., Issaquah, WA, UNITED STATES
 Mannion, Jane, Edmonds, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)
 PI US 2003144494 A1 20030731
 AI US 2002-264283 A1 20021002 (10)
 PRAI US 2002-384531P 20020530 (60)
 US 2001-327135P 20011002 (60)

DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5929
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly ovarian cancer, are disclosed. Illustrative compositions
 comprise one or more ovarian tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 38 OF 135 USPATFULL on STN
 AN 2003:200455 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Mericle, Barbara, Edmonds, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES
 Spies, A. Gregory, Shoreline, WA, UNITED STATES
 Foy, Teresa M., Federal Way, WA, UNITED STATES
 Fan, Liqun, Bellevue, WA, UNITED STATES
 Wang, Tongtong, Medina, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003138438 A1 20030724
 AI US 2002-117982 A1 20020405 (10)
 RLI Continuation-in-part of Ser. No. US 2001-7700, filed on 30 Nov 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun
 2001, PENDING Continuation-in-part of Ser. No. US 2001-850716, filed on
 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-735705,
 filed on 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US
 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-662786, filed on 15 Sep 2000, ABANDONED Continuation-in-part
 of Ser. No. US 2000-643597, filed on 21 Aug 2000, GRANTED, Pat. No. US
 6426072 Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug
 2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on
 28 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-542615,
 filed on 4 Apr 2000, PENDING Continuation-in-part of Ser. No. US
 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-480884, filed on 10 Jan 2000, PENDING Continuation-in-part
 of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr
 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on
 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912,
 filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part
 of Ser. No. US 1998-40802, filed on 18 Mar 1998, ABANDONED
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 7540
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.
 L12 ANSWER 39 OF 135 USPATFULL on STN
 AN 2003:187421 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 King, Gordon E., Shoreline, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
 PI US 2003129207 A1 20030710
 AI US 2002-225486 A1 20020820 (10)
 PRAI US 2001-343517P 20011221 (60)
 US 2001-314221P 20010821 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5617
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly colon cancer, are disclosed. Illustrative compositions

comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 40 OF 135 USPATFULL on STN
AN 2003:187406 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Chenault, Ruth A., Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Fanger, Gary R., UNITED STATES
Harlocker, Susan L., UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003129192 A1 20030710
AI US 2002-212677 A1 20020802 (10)
RLI Continuation-in-part of Ser. No. US 2001-970966, filed on 2 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-825294, filed on 3 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-713550, filed on 14 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-656668, filed on 7 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640173, filed on 15 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-561778, filed on 1 May 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-394374, filed on 10 Sep 1999, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 41 OF 135 USPATFULL on STN
AN 2003:181702 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Fanger, Gary R., Mill Creek, WA, UNITED STATES
Hirst, Shannon Kathleen, Kirkland, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Foy, Teresa M., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003125536 A1 20030703
AI US 2002-212679 A1 20020802 (10)
RLI Continuation-in-part of Ser. No. US 2002-79137, filed on 20 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-924400, filed on 7 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-810936, filed on 16 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-534825, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-289198, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998, GRANTED, Pat. No. US 6344550 Continuation-in-part of Ser. No. US 1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054 Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997,

ABANDONED Continuation-in-part of Ser. No. US 1996-700014, filed on 20 Aug 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-585392, filed on 11 Jan 1996, ABANDONED

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 10446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 42 OF 135 USPATFULL on STN

AN 2003:180313 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Bangur, Chaitanya S., Seattle, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Hill, Paul, Duvall, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003124140 A1 20030703

AI US 2002-198053 A1 20020717 (10)

RLI Continuation-in-part of Ser. No. US 2001-907969, filed on 17 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-884441, filed on 18 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-827271, filed on 4 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-667857, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-636801, filed on 10 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-617747, filed on 17 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-404879, filed on 24 Sep 1999, GRANTED, Pat. No. US 6468546 Continuation-in-part of Ser. No. US 1999-338933, filed on 23 Jun 1999, GRANTED, Pat. No. US 6488931 Continuation-in-part of Ser. No. US 1998-216003, filed on 17 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-215681, filed on 17 Dec 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 101 Drawing Page(s)

LN.CNT 14715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 43 OF 135 USPATFULL on STN

AN 2003:180308 USPATFULL

TI Recombinant intracellular pathogen vaccines and methods for use

IN Horwitz, Marcus A., Los Angeles, CA, UNITED STATES

Harth, Gunter, Los Angeles, CA, UNITED STATES

Tullius, Michael V., Los Angeles, CA, UNITED STATES

PI US 2003124135 A1 20030703

AI US 2002-261981 A1 20020930 (10)

RLI Continuation-in-part of Ser. No. US 2000-550468, filed on 17 Apr 2000,

GRANTED, Pat. No. US 6471967

DT Utility

FS APPLICATION

LREP OPPENHEIMER WOLFF & DONNELLY LLP, 840 NEWPORT CENTER DRIVE, SUITE 700,
NEWPORT BEACH, CA, 92660

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 2045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunogenic compositions for inducing immune responses in an animal host against intracellular pathogen diseases are provided. The immunogenic compositions consist of recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens. Exemplary immunogenic compositions include, but are not limited to, vaccines and immunotherapeutics such as attenuated recombinant ***Mycobacteria*** expressing the major extracellular non-fusion proteins of ***Mycobacteria*** and/or other intracellular pathogens. These exemplary vaccines are shown to produce surprisingly potent protective immune responses in mammals.

L12 ANSWER 44 OF 135 USPATFULL on STN

AN 2003:172755 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Fan, Liqun, Bellevue, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003118599 A1 20030626

AI US 2002-144649 A1 20020510 (10)

RLI Continuation-in-part of Ser. No. US 2001-854133, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-738973, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-704512, filed on 1 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-667170, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640878, filed on 18 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-588937, filed on 5 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-538037, filed on 29 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-518809, filed on 3 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-476235, filed on 30 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-370838, filed on 9 Aug 1999, GRANTED, Pat. No. US 6444425 Continuation-in-part of Ser. No. US 1999-285323, filed on 2 Apr 1999, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 45 OF 135 USPATFULL on STN

AN 2003:159819 USPATFULL

TI Compositions and methods for the therapy and diagnosis of kidney cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Edmonds, WA, UNITED STATES
Gaiger, Alexander, Seattle, WA, UNITED STATES

Gordon, Brian, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003109434 A1 20030612
AI US 2002-102524 A1 20020319 (10)
PRAI US 2001-343340P 20011221 (60)
US 2001-277245P 20010319 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly kidney cancer, are disclosed. Illustrative compositions
comprise one or more kidney tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly kidney cancer.

L12 ANSWER 46 OF 135 USPATFULL on STN
AN 2003:158952 USPATFULL
TI Compositions and methods for delivery of proteins and adjuvants
encapsulated in microspheres
IN Johnson, Mark E., Bellevue, WA, UNITED STATES
Evans, Jay T., Hamilton, MT, UNITED STATES
Kern, Jeffrey A., Hamilton, MT, UNITED STATES
PI US 2003108565 A1 20030612
AI US 2002-192086 A1 20020710 (10)
PRAI US 2001-304590P 20010710 (60)
US 2001-346013P 20011109 (60)
DT Utility
FS APPLICATION
LREP GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER DRIVE WEST, SUITE
1050, LOS ANGELES, CA, 90045
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 1929
AB Hydrophobic ion pairing (HIP) is applied to solubilize proteins and/or
adjuvants in an organic medium. A polymer is cosolubilized in the medium
and microspheres encapsulating the protein and/or adjuvant can be
produced by a single emulsion method. Microspheres prepared by this
method exhibit low initial burst of the protein and gradual release over
time, and elicit a strong and comprehensive immune response.
Compositions comprising a protein and an adjuvant co-encapsulated in
microspheres are provided.

L12 ANSWER 47 OF 135 USPATFULL on STN
AN 2003:152328 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003103994 A1 20030605
AI US 2002-114666 A1 20020401 (10)
RLI Continuation-in-part of Ser. No. US 2001-895828, filed on 28 Jun 2001,
PENDING
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 10295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 48 OF 135 USPATFULL on STN

AN 2003:140131 USPATFULL

TI Compositions and methods for WT1 specific immunotherapy

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Smithgall, Molly, Seattle, WA, UNITED STATES

Moulton, Gus, Seattle, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

Mossman, Sally P., Seattle, WA, UNITED STATES

Evans, Lawrence S., Seattle, WA, UNITED STATES

Spies, A. Gregory, Shoreline, WA, UNITED STATES

Boydston, Jeremy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003095971 A1 20030522

AI US 2001-2603 A1 20011030 (10)

RLI Continuation-in-part of Ser. No. US 2001-938864, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-785019, filed on 15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 42 Drawing Page(s)

LN.CNT 7828

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 49 OF 135 USPATFULL on STN

AN 2003:134554 USPATFULL

TI Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors

IN Johnson, David A., Hamilton, MT, UNITED STATES

Sowell, C. Gregory, Mukilteo, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)

PI US 2003092643 A1 20030515

AI US 2002-43086 A1 20020108 (10)

RLI Continuation-in-part of Ser. No. US 2001-905160, filed on 12 Jul 2001, PENDING Continuation of Ser. No. US 1999-439839, filed on 12 Nov 1999, GRANTED, Pat. No. US 6303347 Continuation-in-part of Ser. No. US 1997-853826, filed on 8 May 1997, GRANTED, Pat. No. US 6113918

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5672

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

L12 ANSWER 50 OF 135 USPATFULL on STN

AN 2003:127603 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Jiang, Yuqiu, Kent, WA, UNITED STATES

Chenault, Ruth A., Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Indirias, Carol Yoseph, Seattle, WA, UNITED STATES

Lodes, Michael J., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Smith, Carole L., Seattle, WA, UNITED STATES

Durham, Margarita, Seattle, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2003087818 A1 20030508

AI US 2002-66543 A1 20020201 (10)

PRAI US 2001-313077P 20010816 (60)

US 2001-290322P 20010511 (60)

US 2001-267400P 20010202 (60)

US 2001-305265P 20010712 (60)

US 2001-267382P 20010207 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 51 OF 135 USPATFULL on STN

AN 2003:119711 USPATFULL

TI Compositions and methods for WT1 specific immunotherapy

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

Cheever, Martin A., Mercer Island, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Smithgall, Molly, Seattle, WA, UNITED STATES

Moulton, Gus, Seattle, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

PI US 2003082196 A1 20030501

AI US 2001-785019 A1 20010215 (9)

RLI Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 46

ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 6242

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 52 OF 135 USPATFULL on STN

AN 2003:119709 USPATFULL

TI Compositions and methods for diagnosis and therapy of malignant mesothelioma

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

Cheever, Martin A., Mercer Island, WA, UNITED STATES

PI US 2003082194 A1 20030501

AI US 2001-791477 A1 20010222 (9)

PRAI US 2000-184070P 20000222 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 50

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 7714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions and methods for the diagnosis and therapy of Wilms' tumor antigen-associated cancers, and in particular, malignant pleural mesothelioma. In particular embodiments, the invention provides new, effective methods, compositions and kits for eliciting immune and T cell response to Wilms' tumor antigen polypeptide-derived antigenic fragments, and methods for the use of such compositions for diagnosis, detection, treatment, monitoring, and/or prevention of human malignant pleural mesothelioma

L12 ANSWER 53 OF 135 USPATFULL on STN

AN 2003:106233 USPATFULL

TI Compositions and methods for the therapy and diagnosis of pancreatic cancer

IN Benson, Darin R., Seattle, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Lodes, Michael J., Seattle, WA, UNITED STATES

Persing, David H., Redmond, WA, UNITED STATES

Hepler, William T., Seattle, WA, UNITED STATES

Jiang, Yuqiu, Kent, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003073144 A1 20030417

AI US 2002-60036 A1 20020130 (10)

PRAI US 2001-333626P 20011127 (60)

US 2001-305484P 20010712 (60)

US 2001-265305P 20010130 (60)

US 2001-267568P 20010209 (60)

US 2001-313999P 20010820 (60)

US 2001-291631P 20010516 (60)

US 2001-287112P 20010428 (60)

US 2001-278651P 20010321 (60)

US 2001-265682P 20010131 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,

particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

L12 ANSWER 54 OF 135 USPATFULL on STN

AN 2003:105856 USPATFULL

TI Compositions and methods for WT1 specific immunotherapy

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Smithgall, Molly, Seattle, WA, UNITED STATES

Moulton, Gus, Seattle, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

Mossman, Sally, Seattle, WA, UNITED STATES

Evans, Lawrence, Seattle, WA, UNITED STATES

Spies, A. Gregory, Shoreline, WA, UNITED STATES

Boydston, Jeremy, Seattle, WA, UNITED STATES

PI US 2003072767 A1 20030417

AI US 2001-938864 A1 20010824 (9)

RLI Continuation-in-part of Ser. No. US 2001-785019, filed on 15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 32 Drawing Page(s)

LN.CNT 7588

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

L12 ANSWER 55 OF 135 USPATFULL on STN

AN 2003:100070 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Jiang, Yuqiu, Kent, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2003069180 A1 20030410

AI US 2002-146502 A1 20020514 (10)

RLI Continuation-in-part of Ser. No. US 2002-46935, filed on 15 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2001-878178, filed on 8 Jun 2001, PENDING

PRAI US 2001-270216P 20010220 (60)

US 2000-210899P 20000609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 56 OF 135 USPATFULL on STN

AN 2003:99223 USPATFULL

TI Compositions and methods for the diagnosis and threatment of herpes simplex virus infection

IN Hosken, Nancy Ann, Seattle, WA, UNITED STATES

McGowan, Patrick, Seattle, WA, UNITED STATES

Sleath, Paul R., Seattle, WA, UNITED STATES

Mossman, Sally P., Seattle, WA, UNITED STATES

Evans, Lawrence S., Seattle, WA, UNITED STATES

Swanson, Ryan M., Seattle, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003068327 A1 20030410

AI US 2002-121988 A1 20020411 (10)

RLI Continuation-in-part of Ser. No. US 2001-894998, filed on 28 Jun 2001, PENDING

PRAI US 2001-277438P 20010320 (60)

US 2000-215458P 20000629 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 10286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.

L12 ANSWER 57 OF 135 USPATFULL on STN

AN 2003:93586 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Fanger, Neil, Seattle, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Durham, Margarita, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Peckham, David W., Seattle, WA, UNITED STATES

Cai, Feng, Lake Forest Park, WA, UNITED STATES

Foy, Teresa M., Federal Way, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003064947 A1 20030403

AI US 2001-7700 A1 20011130 (10)

RLI Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 16032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 58 OF 135 USPATFULL on STN

AN 2003:85829 USPATFULL

TI Lipophilin complexes for use in cancer diagnosis and therapy

IN Dillon, Davin C., Issaquah, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES

PI US 2003059432 A1 20030327

AI US 2001-905673 A1 20010713 (9)

RLI Continuation-in-part of Ser. No. US 2001-780842, filed on 8 Feb 2001, PENDING

PRAI US 2000-215735P 20000628 (60)

US 2000-183495P 20000211 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 3366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of breast, ovarian and prostate cancer are disclosed. Compositions may comprise one or more lipophilin fusion proteins, which comprise at least two different lipophilin-like polypeptides linked by a peptide bond. Such compositions may be used for the prevention and treatment of breast, ovarian and prostate cancer. Diagnostic methods based on detecting the presence of lipophilin complexes, or antibodies thereto, in a patient are also provided.

L12 ANSWER 59 OF 135 USPATFULL on STN

AN 2003:78443 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Henderson, Robert A., Edmonds, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES
 Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
 Johnson, Jeffrey C., Des Moines, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Durham, Margarita, Seattle, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Bangur, Chaitanya S., Seattle, WA, UNITED STATES
 McNabb, Andria, Renton, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003054363 A1 20030320
 AI US 2001-17754 A1 20011029 (10)
 RLI Continuation-in-part of Ser. No. US 2001-902941, filed on 10 Jul 2001,
 PENDING Continuation-in-part of Ser. No. US 2001-849626, filed on 3 May
 2001, PENDING Continuation-in-part of Ser. No. US 2000-736457, filed on
 13 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-702705,
 filed on 30 Oct 2000, PENDING Continuation-in-part of Ser. No. US
 2000-677419, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-671325, filed on 26 Sep 2000, PENDING Continuation-in-part
 of Ser. No. US 2000-658824, filed on 8 Sep 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-651563, filed on 29 Aug 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-614124, filed on 11 Jul
 2000, PENDING Continuation-in-part of Ser. No. US 2000-589184, filed on
 5 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-560406,
 filed on 27 Apr 2000, PENDING Continuation-in-part of Ser. No. US
 2000-546259, filed on 10 Apr 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-533077, filed on 22 Mar 2000, PENDING Continuation-in-part
 of Ser. No. US 2000-519642, filed on 6 Mar 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-476300, filed on 30 Dec 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-466867, filed on 17 Dec
 1999, PENDING Continuation-in-part of Ser. No. US 1999-419356, filed on
 15 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-346492,
 filed on 30 Jun 1999, PENDING
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 8726
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.
 L12 ANSWER 60 OF 135 USPATFULL on STN
 AN 2003:65344 USPATFULL
 TI Compositions and methods for the therapy, diagnosis and monitoring of
 breast cancer
 IN Fling, Steven P., Bainbridge Island, WA, UNITED STATES
 Foy, Teresa M., Federal Way, WA, UNITED STATES
 Clapper, Jonathan D., Seattle, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Johnson, Jeffrey C., Des Moines, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Sutherland, R. Alec, Bothell, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003045468 A1 20030306
 AI US 2002-42945 A1 20020108 (10)
 RLI Continuation-in-part of Ser. No. US 2001-8045, filed on 8 Dec 2001,
 ABANDONED Continuation-in-part of Ser. No. US 2001-757417, filed on 8
 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-580376, filed
 on 26 May 2000, PENDING
 PRAI US 1999-137048P 19990601 (60)

US 1999-136528P 19990528 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 3064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy, diagnosis and monitoring of
breast cancer are disclosed. Compositions may comprise one or more
mammaglobin epitopes, or antibodies or T cells thereto, and may be used,
for example, for the prevention and treatment of breast cancer.
Diagnostic methods based on detecting the presence of mammaglobin
epitopes, or antibodies or T cells thereto, in a sample are also
provided. Also provided are methods for detecting RNA encoding
mammaglobin in patient blood or fractions thereof. These methods may be
used to detect and/or monitor the progression of breast cancer.

L12 ANSWER 61 OF 135 USPATFULL on STN
AN 2003:57071 USPATFULL
TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
Smithgall, Molly D., Seattle, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Cheever, Martin A., Mercer Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Sutherland, R. Alec, Bothell, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003039635 A1 20030227
AI US 2002-125635 A1 20020416 (10)
RLI Continuation-in-part of Ser. No. US 2001-2603, filed on 30 Oct 2001,
PENDING Continuation-in-part of Ser. No. US 2001-938864, filed on 24 Aug
2001, PENDING Continuation-in-part of Ser. No. US 2001-785019, filed on
15 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-685830,
filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US
2000-684361, filed on 6 Oct 2000, PENDING Continuation-in-part of Ser.
No. US 1999-276484, filed on 25 Mar 1999, PENDING Continuation-in-part
of Ser. No. US 1998-164223, filed on 30 Sep 1998, PENDING

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 9204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy of malignant diseases, such as
leukemia and cancer, are disclosed. The compositions comprise one or
more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting
cell presenting a WT1 polypeptide, an antibody that specifically binds
to a WT1 polypeptide; or a T cell that specifically reacts with a WT1
polypeptide. Such compositions may be used, for example, for the
prevention and treatment of metastatic diseases.

L12 ANSWER 62 OF 135 USPATFULL on STN
AN 2003:31085 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Houghton, Raymond L., Bothell, WA, UNITED STATES
Sleath, Paul R., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2003023036 A1 20030130
AI US 2002-76622 A1 20020213 (10)
RLI Continuation-in-part of Ser. No. US 2001-7805, filed on 7 Dec 2001,
PENDING Continuation-in-part of Ser. No. US 2001-834759, filed on 13 Apr
2001, PENDING Continuation-in-part of Ser. No. US 2000-620405, filed on
20 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-604287,
filed on 22 Jun 2000, PENDING Continuation-in-part of Ser. No. US

2000-590751, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-551621, filed on 17 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-433826, filed on 3 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-389681, filed on 2 Sep 1999, PENDING Continuation-in-part of Ser. No. US 1999-339338, filed on 23 Jun 1999, PENDING Continuation-in-part of Ser. No. US 1999-285480, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-222575, filed on 28 Dec 1998, GRANTED, Pat. No. US 6387697

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 14515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 63 OF 135 USPATFULL on STN

AN 2003:23331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003017167 A1 20030123
AI US 2001-904456 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001, PENDING
PRAI US 2001-290240P 20010510 (60)
US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8237

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 64 OF 135 USPATFULL on STN

AN 2003:268131 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, United States
Dillon, Davin C., Issaquah, WA, United States
Mitcham, Jennifer L., Redmond, WA, United States
Harlocker, Susan L., Seattle, WA, United States
Jiang, Yuqiu, Kent, WA, United States
Kalos, Michael D., Seattle, WA, United States
Fanger, Gary R., Mill Creek, WA, United States
Retter, Marc W., Carnation, WA, United States
Stolk, John A., Bothell, WA, United States

Day, Craig H., Seattle, WA, United States
 Vedvick, Thomas S., Federal Way, WA, United States
 Carter, Darrick, Seattle, WA, United States
 Li, Samuel X., Redmond, WA, United States
 Wang, Aijun, Issaquah, WA, United States
 Skeiky, Yasir A. W., Bellevue, WA, United States
 Hepler, William T., Seattle, WA, United States
 Henderson, Robert A., Edmonds, WA, United States
 PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 6630305 B1 20031007
 AI US 2000-685166 20001010 (9)
 RLI Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000
 Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000
 Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000
 Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug 2000
 Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000
 Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000
 Continuation-in-part of Ser. No. US 2000-510737, filed on 12 May 2000
 Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000
 Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000,
 now abandoned Continuation-in-part of Ser. No. US 2000-483672, filed on
 14 Jan 2000 Continuation-in-part of Ser. No. US 1999-443686, filed on 18
 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-439313,
 filed on 12 Nov 1999, now patented, Pat. No. US 6329505
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Brusca, John S.; Assistant Examiner: Zhou, Shubo
 LREP Seed IP Law Group
 CLMN Number of Claims: 4
 ECL Exemplary Claim: 1
 DRWN 17 Drawing Figure(s); 14 Drawing Page(s)
 LN.CNT 7044
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly prostate cancer, are disclosed. Illustrative compositions
 comprise one or more prostate-specific polypeptides, immunogenic
 portions thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly prostate cancer.
 L12 ANSWER 65 OF 135 USPATFULL on STN
 AN 2003:240306 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of ovarian cancer
 IN Xu, Jiangchun, Bellevue, WA, United States
 Stolk, John A., Bothell, WA, United States
 PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 6617109 B1 20030909
 AI US 2000-713550 20001114 (9)
 RLI Continuation-in-part of Ser. No. US 2000-656668, filed on 7 Sep 2000
 Continuation-in-part of Ser. No. US 2000-640173, filed on 15 Aug 2000
 Continuation-in-part of Ser. No. US 2000-561778, filed on 1 May 2000,
 now abandoned Continuation-in-part of Ser. No. US 1999-394374, filed on
 10 Sep 1999, now abandoned
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Zeman, Mary K.; Assistant Examiner: Clow, Lori A.
 LREP Barzee, Eric M., Lingenfelter, Susan E., Shumate, Cynthia L.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1,3
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 6573
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly ovarian cancer, are disclosed. Illustrative compositions
 comprise one or more ovarian tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention

and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 66 OF 135 USPATFULL on STN

AN 2003:234669 USPATFULL

TI Ovarian tumor sequences and methods of use therefor

IN Xu, Jiangchun, Bellevue, WA, United States

Stolk, John A., Bothell, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6613515 B1 20030902

AI US 2000-640173 20000815 (9)

RLI Continuation-in-part of Ser. No. US 2000-561778, filed on 1 May 2000,
now abandoned Continuation-in-part of Ser. No. US 1999-394374, filed on
10 Sep 1999, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Zeman, Mary K.

LREP Barzee, Eric M., Lingenfelter, Susan E., Shumate, Cynthia L.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1,2

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 6184

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such
as ovarian cancer, are disclosed. Compositions may comprise one or more
ovarian carcinoma proteins, portions thereof, polynucleotides that
encode such portions or antibodies or immune system cells specific for
such proteins. Such compositions may be used, for example, for the
prevention and treatment of diseases such as ovarian cancer.
Polypeptides and polynucleotides as provided herein may further be used
for the detection and monitoring of ovarian cancer.

L12 ANSWER 67 OF 135 USPATFULL on STN

AN 2003:190560 USPATFULL

TI Compounds and methods for immunotherapy and diagnosis of tuberculosis

IN Reed, Steven G., Bellevue, WA, United States

Skeiky, Yasir A. W., Seattle, WA, United States

Dillon, Davin C., Redmond, WA, United States

Campos-Neto, Antonio, Bainbridge Island, WA, United States

Houghton, Raymond, Bothell, WA, United States

Vedvick, Thomas S., Federal Way, WA, United States

Twardzik, Daniel R., Bainbridge Island, WA, United States

Lodes, Michael J., Seattle, WA, United States

Hendrickson, Ronald C., Seattle, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6592877 B1 20030715

AI US 1998-72967 19980505 (9)

RLI Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998,
now abandoned Continuation-in-part of Ser. No. US 1997-942578, filed on
1 Oct 1997, now abandoned Continuation-in-part of Ser. No. US
1997-818112, filed on 13 Mar 1997, now patented, Pat. No. US 6290969
Continuation-in-part of Ser. No. US 730510, now abandoned
Continuation-in-part of Ser. No. US 1996-680574, filed on 12 Jul 1996,
now abandoned Continuation-in-part of Ser. No. US 1996-659683, filed on
5 Jun 1996, now abandoned Continuation-in-part of Ser. No. US
1996-620874, filed on 22 Mar 1996, now abandoned Continuation-in-part of
Ser. No. US 1995-533634, filed on 22 Sep 1995, now abandoned
Continuation-in-part of Ser. No. US 1995-523436, filed on 1 Sep 1995,
now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 19 Drawing Page(s)

LN.CNT 8747

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for inducing protective immunity against
tuberculosis are disclosed. The compounds provided include polypeptides
that contain at least one immunogenic portion of one or more M.
tuberculosis proteins and DNA molecules encoding such polypeptides. Such

compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

L12 ANSWER 68 OF 135 USPATFULL on STN

AN 2003:95815 USPATFULL

TI Fusion proteins of ***mycobacterium*** tuberculosis antigens and their uses

IN Skeiky, Yasir, Seattle, WA, United States

Alderson, Mark, Bainbridge Island, WA, United States

Campos-Neto, Antonio, Bainbridge Island, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6544522 B1 20030408

AI US 1998-223040 19981230 (9)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 32 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 1190

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins of

Mycobacterium tuberculosis antigens. In particular, it relates to two fusion proteins, each of which contains three individual M. tuberculosis antigens, and a fusion protein of two M. tuberculosis antigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.

L12 ANSWER 69 OF 135 USPATFULL on STN

AN 2003:67678 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, United States

Fan, Liqun, Bellevue, WA, United States

Kalos, Michael D., Seattle, WA, United States

Bangur, Chaitanya S., Seattle, WA, United States

Hosken, Nancy A., Seattle, WA, United States

Fanger, Gary R., Mill Creek, WA, United States

Li, Samuel X., Redmond, WA, United States

Wang, Aijun, Issaquah, WA, United States

Skeiky, Yasir A. W., Bellevue, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6531315 B1 20030311

AI US 2000-606421 20000628 (9)

RLI Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000

Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000

Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000

Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999

Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999

Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999

Continuation of Ser. No. WO 1999-US5798, filed on 17 Mar 1999

Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998

Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998,

now patented, Pat. No. US 6312695 Continuation-in-part of Ser. No. US

1998-40802, filed on 18 Mar 1998, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Priebe, Scott D.; Assistant Examiner: Chen, Shin-Lin

LREP Seed Intellectual Property Law Group PLLC

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 11830

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such

compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 70 OF 135 USPATFULL on STN

AN 2003:6971 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, United States

Bangur, Chaitanya S., Seattle, WA, United States

Lodes, Michael J., Seattle, WA, United States

Fanger, Gary R., Mill Creek, WA, United States

Vedvick, Thomas S., Federal Way, WA, United States

Carter, Darrick, Seattle, WA, United States

Retter, Marc W., Carnation, WA, United States

Mannion, Jane, Edmonds, WA, United States

Fan, Liqun, Bellevue, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6504010 B1 20030107

AI US 2000-702705 20001030 (9)

RLI Continuation-in-part of Ser. No. US 2000-677419, filed on 6 Oct 2000

Continuation-in-part of Ser. No. US 2000-671325, filed on 26 Sep 2000

Continuation-in-part of Ser. No. US 2000-658824, filed on 8 Sep 2000

Continuation-in-part of Ser. No. US 2000-651563, filed on 29 Aug 2000

Continuation-in-part of Ser. No. US 2000-614124, filed on 11 Jul 2000

Continuation-in-part of Ser. No. US 2000-589184, filed on 5 Jun 2000

Continuation-in-part of Ser. No. US 2000-560406, filed on 27 Apr 2000

Continuation-in-part of Ser. No. US 2000-546259, filed on 10 Apr 2000

Continuation-in-part of Ser. No. US 2000-533077, filed on 22 Mar 2000

Continuation-in-part of Ser. No. US 2000-519642, filed on 6 Mar 2000

Continuation-in-part of Ser. No. US 1999-476300, filed on 30 Dec 1999

Continuation-in-part of Ser. No. US 1999-466867, filed on 17 Dec 1999

Continuation-in-part of Ser. No. US 1999-419356, filed on 15 Oct 1999

Continuation-in-part of Ser. No. US 1999-346492, filed on 30 Jun 1999,

now abandoned Continuation-in-part of Ser. No. WO 1999-US18061, filed on 30 Jun 1999

DT Utility

FS GRANTED

EXNAM Primary Examiner: Brusca, John S.

LREP Seed Intellectual Property Law Group PLLC

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 5517

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 71 OF 135 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 5

AN 2003:223639 BIOSIS

DN PREV200300223639

TI Differential effects of control and antigen-specific T cells on intracellular ***mycobacterial*** growth.

AU Worku, S.; Hoft, D. F. [Reprint Author]

CS Division of Infectious Diseases and Immunology, St. Louis University Health Sciences Center, Saint Louis, MO, 63110, USA
hoftdf@slu.edu

SO Infection and Immunity, (April 2003) Vol. 71, No. 4, pp. 1763-1773. print. ISSN: 0019-9567 (ISSN print).

DT Article

LA English

ED Entered STN: 7 May 2003

Last Updated on STN: 7 May 2003

AB We investigated the effects of peripheral blood mononuclear cells expanded

with irrelevant control and ***mycobacterial*** antigens on the intracellular growth of ***Mycobacterium*** bovis bacillus Calmette-Guerin (BCG) in human macrophages. More than 90% of the cells present after 1 week of in vitro expansion were CD3+. T cells were expanded from purified protein derivative-negative controls, persons with latent tuberculosis, and BCG-vaccinated individuals. T cells expanded with nonmycobacterial antigens enhanced the intracellular growth of BCG in suboptimal cultures of macrophages. T cells expanded with live BCG or lysates of ***Mycobacterium*** tuberculosis directly inhibited intracellular BCG. Recent intradermal BCG vaccination significantly enhanced the inhibitory activity of T cells expanded with ***mycobacterial*** antigens ($P < 0.02$), consistent with the induction of memory-immune inhibitory T-cell responses. Selected ***mycobacterial*** antigens (Mtb41>lipoarabinomannan>38kd>Ag85B> ***Mtb39***) expanded inhibitory T cells, demonstrating the involvement of antigen-specific T cells in intracellular BCG inhibition. We studied the T-cell subsets and molecular mechanisms involved in the memory-immune inhibition of intracellular BCG. ***Mycobacteria*** -specific gammadelta T cells were the most potent inhibitors of intracellular BCG growth. Direct contact between T cells and macrophages was necessary for the BCG growth-enhancing and inhibitory activities mediated by control and ***mycobacteria*** -specific T cells, respectively. Increases in tumor necrosis factor alpha, interleukin-6, transforming growth factor beta, and vascular endothelial growth factor mRNA expression were associated with the enhancement of intracellular BCG growth. Increases in gamma interferon, FAS, FAS ligand, perforin, granzyme, and granulysin mRNA expression were associated with intracellular BCG inhibition. These culture systems provide in vitro models for studying the opposing T-cell mechanisms involved in ***mycobacterial*** survival and protective host immunity.

L12 ANSWER 72 OF 135 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 6

AN 2003045360 EMBASE

TI Up-to-date understanding of tuberculosis immunity.

AU Mitsuyama M.; Akagawa K.

CS M. Mitsuyama, Department of Microbiology, Kyoto Univ. Grad. School of Medicine, Yoshida-Konocho, Sakyo-ku, Kyoto-shi, Kyoto 606-8501, Japan. mituyama@mb.med.kyoto-u.ac.jp

SO Kekkaku, (1 Jan 2003) 78/1 (51-55).
ISSN: 0022-9776 CODEN: KEKKAG

CY Japan

DT Journal; Conference Article

FS 004 Microbiology
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA Japanese

SL English; Japanese

AB This symposium was organized to provide the up-to-date knowledge on tuberculosis immunity, especially on the understanding of cytokines or Th1 cells involved in pathophysiology/protective immunity and vaccine development. Dr. Kazuo Kobayashi (Osaka City Univ.) reported their findings on the immune response to bioactive lipid component from M. tuberculosis, trehalose-dimycolate (TDM) and sulfolipid (SL) in mice. Their unique and novel finding was that TDM is capable of inducing T-dependent immune response in euthymic mice. The specific immune response in TDM-immune mice was consisting of CD4+ cell response and expression of chemokines, inflammatory cytokines and then TH1-related cytokines. In contrast, SL did not show such an activity. TDM may be one of the protective antigens and may modulate the specific immune response of the host. Dr. Isamu Sugawara's group (JATA) has examined the involvement of various cytokines in the host response to aerosolic infection with virulent strain of M. tuberculosis by using cytokine-knockout mice. The single deletion of IFN-.gamma. or TNF .alpha. resulted in a severe lesion of multiple necrosis without granuloma, and cytokine mRNA level other than knocked out cytokine was normal, suggesting that IFN-.gamma. and TNF .alpha. are principally important cytokines. In knockout mice for IL-12 or IL-18, necrotic lesion was not induced after infection and the pathological change was not so significant as in IFN-.gamma. / TNF .alpha. knockout mice. By using IFN-.gamma. knockout mice, it became possible to generate a granulomatous lesion with central necrosis and cavity

resembling the lesion in humans. These mouse model appeared to be useful in the analysis of pathophysiology of human tuberculosis. Dr. Kazuyoshi Kawakami (Ryukyu Univ.) reported the importance of TH1 cytokines in anti-tuberculous immunity. By using IL-12, IL-18 knockout mice or double knockout mice, it was shown that IL-12 exhibits more important role than IL-18 in the protection. A possible contribution of IL-23 was also suggested. In most of the clinical cases of tuberculosis, the production of IL-12, IL-18 and IFN- γ is increased, however, the group of relatively lower cytokine production did not respond well to the treatment. In addition, the plasma level of one of the chemokines, IP-10, was shown to be an indicator for the severity of the disease. Thus, some cytokines appear to be employable for the novel treatment in the near future. Dr. Saburo Yamamoto (NIH) summarized the recent advance in the understanding of biological function of CpG motifs. Immunostimulatory DNA is effective in the modulation of TH1/TH2 polarity and the enhancement of protective immunity to M. tuberculosis in animals. CpG motif (immunostimulatory DNA) appears to exert its activity by signaling cascade via TLR9 resulting in NF- κ B activation and cytokine gene expression. Analysis of basic mechanism of action by CpG motif should pave the way to the clinical application in the future. Dr. Masaji Okada (Kinki Chuo Hospital) reported the current situation in the development of novel vaccines against tuberculosis. They have extensively constructed and examined the efficacy of various types of vaccines including subunit, DNA and recombinant BCG vaccines. Various vector systems have been tested for DNA vaccine. As immunizing antigens, a-Ag, ESAT-6, HSP65, 38kD-lipoprotein and so on have been employed. A large body of experimental data are accumulating for final evaluation, and among them, it is noteworthy to mention that HSP65DNA+IL-12DNA was 100 times more effective than conventional BCG in animal model. Among subunit vaccines, ***Mtb72f*** vaccine appears to be one of the promising candidates. In addition to the trial with various candidates, they have established a new mouse model, SCID/human PBL. This model animal has been employed for the development of vaccine effective for the induction of ESAT-6-specific human T cells.

L12 ANSWER 73 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7

AN 2002:256743 CAPLUS

DN 136:278138

TI Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

IN Subjeck, John R.; Henderson, Robert A.; Repasky, Elizabeth A.; Kazim, Latif; Wang, Xiang-yang

PA USA

SO U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U. S. Ser. No. 676,340.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002039583	A1	20020404	US 2001-872186	20010601
	WO 2002098360	A2	20021212	WO 2002-US17642	20020603
	WO 2002098360	A3	20030220		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-156821P	P	19990930		
	US 1999-163168P	P	19991102		
	US 2000-215497P	P	20000630		
	US 2000-676340	A2	20000929		
	US 2001-872186	A	20010601		

AB Pharmaceutical compns. comprising a stress protein complex and related mols. encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the

stress protein complex can be assocd. with a cancer or an infectious disease. Examples of immunogenic polypeptides include, but are not limited to, her2/neu ICD and ***Mycobacterium*** tuberculosis antigens. The pharmaceutical compns. of the invention can be administered to a subject, thereby providing methods for inhibiting infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or an infected cell. Included in the invention are T cells produced by this method and a pharmaceutical compn. comprising such T cells.

L12 ANSWER 74 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:716453 CAPLUS
DN 137:246530

TI Fusion proteins of Leishmania antigens and antigens of pathogens for diagnostic or vaccine use
IN Skeiky, Yasir; Brannon, Mark; Guderian, Jeffrey
PA Corixa Corporation, USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072792	A2	20020919	WO 2002-US8223	20020313
	WO 2002072792	C1	20030807		
	WO 2002072792	C2	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003175294 A1 20030918 US 2002-98732 20020313

PRAI US 2001-275837P P 20010313

AB Fusion proteins of antigens of Leishmania and foreign antigens that may be useful in the diagnosis, prophylaxis or treatment of disease are described. The Leishmania antigen may be TSA (thiol-specific antioxidant), LeIF (initiation factor 4A), M15 or 6H. The invention also provides an expression cassette comprising the recombinant nucleic acid mol., host cells comprising the expression cassette, compns., fusion polypeptides, and methods of their use in diagnosis or in generating a protective immune response in hosts. The genes may be codon optimized for expression in a specific host. Specifically, fusion proteins with antigens of ***Mycobacterium*** tuberculosis are described. Construction of codon optimized genes for fusion proteins of Leishmania antigens and ***Mycobacterium*** tuberculosis antigens and their expression in HEK cells is demonstrated.

L12 ANSWER 75 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:275811 CAPLUS
DN 136:308523

TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander; McNeill, Patricia D.; Smithgall, Molly; Moulton, Gus; Vedvick, Thomas S.; Sleath, Paul R.; Mossman, Sally; Evans, Lawrence; Spies, A. Gregory; Boydston, Jeremy
PA Corixa Corporation, USA
SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028414	A1	20020411	WO 2001-US31139	20011003
	WO 2002028414	B1	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003082196	A1	20030501	US 2001-785019	20010215
US 2003072767	A1	20030417	US 2001-938864	20010824
AU 2001096608	A5	20020415	AU 2001-96608	20011003
EP 1328287	A1	20030723	EP 2001-977493	20011003

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004510425	T2	20040408	JP 2002-532238	20011003
---------------	----	----------	----------------	----------

PRAI US 2000-684361 A 20001006

US 2000-685830 A 20001009

US 2001-785019 A 20010215

US 2001-938864 A 20010824

US 1998-164223 A2 19980930

US 1999-276484 A2 19990325

WO 2001-US31139 W 20011003

AB Comps. and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The comps. comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such comps. may be used, for example, for the prevention and treatment of metastatic diseases.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 76 OF 135 USPATFULL on STN

AN 2002:343943 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Bangur, Chaitanya S., Seattle, WA, UNITED STATES
Fanger, Gary Richard, Mill Creek, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Switzer, Ann P., Seattle, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES

PI US 2002197669 A1 20021226

AI US 2001-849626 A1 20010503 (9)

RLI Continuation-in-part of Ser. No. US 2000-736457, filed on 13 Dec 2000, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7369

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 77 OF 135 USPATFULL on STN

AN 2002:337964 USPATFULL

TI Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies

IN Hand-Zimmermann, Susan, Redmond, WA, UNITED STATES
Cheever, Martin A., Mercer Island, WA, UNITED STATES

Foy, Teresa M., Federal Way, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2002193329 A1 20021219
 AI US 2001-930125 A1 20010814 (9)
 PRAI US 2001-270520P 20010221 (60)
 US 2000-236428P 20000928 (60)
 US 2000-225152P 20000814 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Page(s)
 LN.CNT 4874

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly Her-2/neu-associated cancers, are disclosed. Illustrative compositions comprise one or more Her-2/neu polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of Her-2/neu-associated malignancies.

L12 ANSWER 78 OF 135 USPATFULL on STN

AN 2002:337931 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Dillon, Davin C., Issaquah, WA, UNITED STATES
 Mitcham, Jennifer L., Redmond, WA, UNITED STATES
 Harlocker, Susan L., Seattle, WA, UNITED STATES
 Jiang, Yuqiu, Kent, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 Day, Craig H., Shoreline, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Li, Samuel X., Redmond, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 Hural, John, Bainbridge Island, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Houghton, Raymond L., Bothell, WA, UNITED STATES
 Bassols, Carlota Vinals y de, Rixensart, BELGIUM
 Foy, Teresa M., Federal Way, WA, UNITED STATES

PI US 2002193296 A1 20021219

AI US 2001-895814 A1 20010629 (9)

RLI Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-759143, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part of Ser.

No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999, PENDING Continuation-in-part of Ser. No. US 1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1999-232149, filed on 15 Jan 1999, PENDING
Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb 1998, PATENTED Continuation-in-part of Ser. No. US 1998-20956, filed on 9 Feb 1998, PATENTED Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25 Feb 1997, ABANDONED

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 7973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 79 OF 135 USPATFULL on STN
AN 2002:337404 USPATFULL
TI Compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcam, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
y de Bassols, Carlota Vinals, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES

PI US 2002192763 A1 20021219
AI US 2001-895793 A1 20010629 (9)
RLI Continuation-in-part of Ser. No. US 2001-822827, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-679272, filed on 4 Oct 2000, PENDING
PRAI US 2000-157455P 20000417 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 14

ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 7578

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 80 OF 135 USPATFULL on STN

AN 2002:323328 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Lodes, Michael J., Seattle, WA, UNITED STATES

Mohamath, Raodoh, Seattle, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

Benson, Darin R., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA (U.S. corporation)

PI US 2002183499 A1 20021205

AI US 2001-854133 A1 20010511 (9)

RLI Continuation-in-part of Ser. No. US 2000-738973, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-704512, filed on 1 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-667170, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640878, filed on 18 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-588937, filed on 5 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-538037, filed on 29 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-518809, filed on 3 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-476235, filed on 30 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-370838, filed on 9 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1999-285323, filed on 2 Apr 1999, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5707

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 81 OF 135 USPATFULL on STN

AN 2002:323085 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Mitcham, Jennifer L., Redmond, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Jiang, Yuqiu, Kent, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES

Day, Craig H., Shoreline, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Vinals y de Bassols, Carlota, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002183251 A1 20021205
AI US 2001-12896 A1 20011210 (10)

RLI Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun 2001,
PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May
2001, PENDING Continuation-in-part of Ser. No. US 2001-780669, filed on
9 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-759143,
filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US
2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser.
No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part
of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000,
PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug
2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on
9 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783,
filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser.
No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part
of Ser. No. US 2000-568100, filed on 9 May 2000, PENDING
Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed on 14
Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed
on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US
1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505
Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999,
GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US
1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser.
No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part
of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998,
PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb
1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US
1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,
ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25
Feb 1997, ABANDONED

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 8810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly prostate cancer, are disclosed. Illustrative compositions
comprise one or more prostate-specific polypeptides, immunogenic
portions thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 82 OF 135 USPATFULL on STN

AN 2002:322030 USPATFULL

TI Compounds for immunotherapy and diagnosis of colon cancer and methods
for their use

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES
Benson, Darin R., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Smith, Carole L., Seattle, WA, UNITED STATES
King, Gordon E., Shoreline, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002182191 A1 20021205

AI US 2001-25380 A1 20011219 (10)

RLI Continuation-in-part of Ser. No. US 2001-922217, filed on 3 Aug 2001,
PENDING Continuation-in-part of Ser. No. US 2001-833263, filed on 10 Apr
2001, PENDING Continuation-in-part of Ser. No. US 2000-649811, filed on
28 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-609448,
filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-575251, filed on 19 May 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-519444, filed on 6 Mar 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-504629, filed on 15 Feb 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-480321, filed on 10
Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-476296,
filed on 30 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US
1999-454150, filed on 2 Dec 1999, ABANDONED Continuation-in-part of Ser.
No. US 1999-444252, filed on 19 Nov 1999, PENDING Continuation-in-part
of Ser. No. US 1999-401064, filed on 22 Sep 1999, PENDING
Continuation-in-part of Ser. No. US 1999-347496, filed on 2 Jul 1999,
PENDING Continuation-in-part of Ser. No. US 1998-221298, filed on 23 Dec
1998, GRANTED, Pat. No. US 6284241

PRAI WO 1999-US30909 19991223

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5203

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such
as colon cancer, are disclosed. Compositions may comprise one or more
colon tumor proteins, immunogenic portions thereof, or polynucleotides
that encode such portions. Alternatively, a therapeutic composition may
comprise an antigen presenting cell that expresses a colon tumor
protein, or a T cell that is specific for cells expressing such a
protein. Such compositions may be used, for example, for the prevention
and treatment of diseases such as colon cancer. Diagnostic methods based
on detecting a colon tumor protein, or mRNA encoding such a protein, in
a sample are also provided.

L12 ANSWER 83 OF 135 USPATFULL on STN

AN 2002:315084 USPATFULL

TI HER-2/neu fusion proteins

IN Cheever, Martin A., Mercer Island, WA, UNITED STATES

Gheysen, Dirk, Rixensart, BELGIUM

PI US 2002177567 A1 20021128

AI US 2001-854356 A1 20010509 (9)

RLI Division of Ser. No. US 2000-493480, filed on 28 Jan 2000, PENDING

PRAI US 1999-117976P 19990129 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 92

ECL Exemplary Claim: 1

DRWN 47 Drawing Page(s)

LN.CNT 4875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, Viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.

L12 ANSWER 84 OF 135 USPATFULL on STN

AN 2002:315070 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Jiang, Yuqiu, Kent, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)

PI US 2002177552 A1 20021128

AI US 2001-878178 A1 20010608 (9)

PRAI US 2001-270216P 20010220 (60)

US 2000-210899P 20000609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4006

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 85 OF 135 USPATFULL on STN

AN 2002:314395 USPATFULL

TI Hybrids of M. tuberculosis antigens

IN Andersen, Peter, Bronshoj, DENMARK

Olsen, Anja Weinreich, Soborg, DENMARK

Skjot, Rikke Louise Vinther, Hedeheusene, DENMARK

Rasmussen, Peter Birk, Frederiksberg, DENMARK

PI US 2002176867 A1 20021128

AI US 2001-805427 A1 20010313 (9)

RLI Continuation-in-part of Ser. No. US 1998-246191, filed on 30 Dec 1998, ABANDONED

PRAI DK 1997-1277 19971110

US 1998-70488P 19980105 (60)

US 1997-44624P 19970418 (60)

DT Utility

FS APPLICATION

LREP Thomas J. Kowalski, c/o FROMMER LAWRENCE & HAUG LLP, 745 Fifth Avenue, New York, NY, 10151

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 2157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from ***Mycobacterium*** tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.

L12 ANSWER 86 OF 135 USPATFULL on STN
AN 2002:308507 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Stolk, John A., UNITED STATES
Molesh, David Alan, UNITED STATES
Fling, Steven P., UNITED STATES
Xu, Jiangchun, UNITED STATES
PI US 2002173638 A1 20021121
US 6720146 B2 20040413
AI US 2001-970966 A1 20011002 (9)
RLI Continuation-in-part of Ser. No. US 2001-825294, filed on 3 Apr 2001,
PENDING Continuation-in-part of Ser. No. US 2000-713550, filed on 14 Nov
2000, PENDING Continuation-in-part of Ser. No. US 2000-656668, filed on
7 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640173,
filed on 15 Aug 2000, PENDING Continuation-in-part of Ser. No. US
2000-561778, filed on 1 May 2000, PENDING Continuation-in-part of Ser.
No. US 1999-394374, filed on 10 Sep 1999, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7870
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 87 OF 135 USPATFULL on STN
AN 2002:307829 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Henderson, Robert A., Edmonds, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Johnson, Jeffrey C., Des Moines, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Durham, Margarita, Seattle, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Bangur, Chaitanya S., Seattle, WA, UNITED STATES
McNabb, Andria, Renton, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002172952 A1 20021121
AI US 2001-902941 A1 20010710 (9)
RLI Continuation-in-part of Ser. No. US 2001-849626, filed on 3 May 2001,
PENDING Continuation-in-part of Ser. No. US 2000-736457, filed on 13 Dec
2000, PENDING Continuation-in-part of Ser. No. US 2000-702705, filed on
30 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-677419,
filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US
2000-671325, filed on 26 Sep 2000, PENDING Continuation-in-part of Ser.
No. US 2000-658824, filed on 8 Sep 2000, PENDING Continuation-in-part of
Ser. No. US 2000-651563, filed on 29 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-614124, filed on 11 Jul 2000,
PENDING Continuation-in-part of Ser. No. US 2000-589184, filed on 5 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-560406, filed on
27 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-546259,
filed on 10 Apr 2000, PENDING Continuation-in-part of Ser. No. US
2000-533077, filed on 22 Mar 2000, PENDING Continuation-in-part of Ser.
No. US 2000-519642, filed on 6 Mar 2000, PENDING Continuation-in-part of
Ser. No. US 1999-476300, filed on 30 Dec 1999, PENDING
Continuation-in-part of Ser. No. US 1999-466867, filed on 17 Dec 1999,
PENDING Continuation-in-part of Ser. No. US 1999-419356, filed on 15 Oct
1999, PENDING Continuation-in-part of Ser. No. US 1999-346492, filed on

30 Jun 1999, PENDING
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8470

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 88 OF 135 USPATFULL on STN

AN 2002:301592 USPATFULL

TI Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity

IN Reiner, Peter B., Vancouver, CANADA
Connop, Bruce P., Vancouver, CANADA
Pollard, Michelle, Vancouver, CANADA

PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S. corporation)

PI US 2002169137 A1 20021114

AI US 2002-72621 A1 20020208 (10)

PRAI US 2001-267975P 20010209 (60)

US 2001-309256P 20010731 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 3827

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the discovery that expression of amyloid precursor protein is regulated by the expression of an ABC transporter. The invention therefore provides methods and compositions for modulating amyloid precursor protein expression in a brain cell, thereby preventing or inhibiting pathological .beta.-amyloid plaque formation in conditions such as Alzheimer's disease.

L12 ANSWER 89 OF 135 USPATFULL on STN

AN 2002:301094 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES
Bangur, Chaitanya S., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Mannion, Jane, Edmonds, WA, UNITED STATES
Fan, Liqun, Bellevue, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES

PI US 2002168637 A1 20021114

US 6509448 B2 20030121

AI US 2000-736457 A1 20001213 (9)

RLI Continuation-in-part of Ser. No. US 2000-702705, filed on 30 Oct 2000,
PENDING Continuation-in-part of Ser. No. US 2000-677419, filed on 6 Oct
2000, PENDING Continuation-in-part of Ser. No. US 2000-671325, filed on
26 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-658824,
filed on 8 Sep 2000, PENDING Continuation-in-part of Ser. No. US
2000-651563, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser.
No. US 2000-614124, filed on 11 Jul 2000, PENDING Continuation-in-part

of Ser. No. US 2000-589184, filed on 5 Jun 2000, PENDING
Continuation-in-part of Ser. No. US 2000-560406, filed on 27 Apr 2000,
PENDING Continuation-in-part of Ser. No. US 2000-546259, filed on 10 Apr
2000, PENDING Continuation-in-part of Ser. No. US 2000-533077, filed on
22 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2000-519642,
filed on 6 Mar 2000, PENDING Continuation-in-part of Ser. No. US
1999-476300, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser.
No. US 1999-466867, filed on 17 Dec 1999, PENDING Continuation-in-part
of Ser. No. US 1999-419356, filed on 15 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-346492, filed on 30 Jun 1999,
PENDING Continuation-in-part of Ser. No. WO 1999-US18061, filed on 30
Jun 1999, UNKNOWN

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly lung cancer, are disclosed. Illustrative compositions
comprise one or more lung tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 90 OF 135 USPATFULL on STN

AN 2002:295321 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Frudakis, Tony N., Sarasota, FL, UNITED STATES
Reed, Steven G., Bellevue, WA, UNITED STATES
Smith, John M., Columbia Heights, MN, UNITED STATES
Misher, Lynda E., Seattle, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Deng, Ta, Edmonds, WA, UNITED STATES

PI US 2002165371 A1 20021107
AI US 2001-924400 A1 20010807 (9)
RLI Continuation-in-part of Ser. No. US 2001-810936, filed on 16 Mar 2001,
PENDING Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct
2000, PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on
8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-577505,
filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US
2000-534825, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser.
No. US 1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part
of Ser. No. US 1999-289198, filed on 9 Apr 1999, PENDING
Continuation-in-part of Ser. No. US 1998-62451, filed on 17 Apr 1998,
GRANTED, Pat. No. US 6344550 Continuation-in-part of Ser. No. US
1997-991789, filed on 11 Dec 1997, GRANTED, Pat. No. US 6225054
Continuation-in-part of Ser. No. US 1997-838762, filed on 9 Apr 1997,
ABANDONED A 371 of International Ser. No. WO 1997-US485, filed on 10 Jan
1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-585392, filed on
11 Jan 1996, ABANDONED

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 8977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 91 OF 135 USPATFULL on STN

AN 2002:294306 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002164345 A1 20021107
AI US 2001-42125 A1 20011018 (10)
PRAI US 2000-242321P 20001020 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 92 OF 135 USPATFULL on STN

AN 2002:280566 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002156011 A1 20021024
AI US 2002-46935 A1 20020115 (10)
RLI Continuation-in-part of Ser. No. US 2001-878178, filed on 8 Jun 2001, PENDING
PRAI US 2001-270216P 20010220 (60)
US 2000-210899P 20000609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4098

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 93 OF 135 USPATFULL on STN

AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 94 OF 135 USPATFULL on STN

AN 2002:272466 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Durham, Margarita, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2002150581 A1 20021017
AI US 2001-7805 A1 20011207 (10)
RLI Continuation-in-part of Ser. No. US 2001-834759, filed on 13 Apr 2001,
PENDING Continuation-in-part of Ser. No. US 2000-620405, filed on 20 Jul
2000, PENDING Continuation-in-part of Ser. No. US 2000-604287, filed on
22 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-590751,
filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US
2000-551621, filed on 17 Apr 2000, PENDING Continuation-in-part of Ser.
No. US 1999-433826, filed on 3 Nov 1999, PENDING Continuation-in-part of
Ser. No. US 1999-389681, filed on 2 Sep 1999, PENDING
Continuation-in-part of Ser. No. US 1999-339338, filed on 23 Jun 1999,
PENDING Continuation-in-part of Ser. No. US 1999-285480, filed on 2 Apr
1999, PENDING Continuation-in-part of Ser. No. US 1998-222575, filed on
28 Dec 1998, GRANTED, Pat. No. US 6387697
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 14059

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions

comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 95 OF 135 USPATFULL on STN

AN 2002:266264 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES

Durham, Margarita, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

Peckham, David W., Seattle, WA, UNITED STATES

Fanger, Neil, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)

PI US 2002147143 A1 20021010

AI US 2001-897778 A1 20010628 (9)

RLI Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998, PATENTED Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 15138

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 96 OF 135 USPATFULL on STN

AN 2002:265851 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Dillon, Davin C., Issaquah, WA, UNITED STATES

Day, Craig H., Shoreline, WA, UNITED STATES

Jiang, Yuqiu, Kent, WA, UNITED STATES

Houghton, Raymond L., Bothell, WA, UNITED STATES

Mitcham, Jennifer L., Redmond, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

McNeill, Patricia D., Federal Way, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Bennigton, Angela Ann, Seattle, WA, UNITED STATES

Zehentner, Barbara, Bainbridge Island, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

PI US 2002146727 A1 20021010

AI US 2001-10742 A1 20011130 (10)

RLI Continuation-in-part of Ser. No. US 2001-910689, filed on 20 Jul 2001,
PENDING Continuation-in-part of Ser. No. US 2001-778320, filed on 6 Feb
2001, PENDING Continuation-in-part of Ser. No. US 2000-571025, filed on
15 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-545068,
filed on 7 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-523586, filed on 10 Mar 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-510662, filed on 22 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 1999-451651, filed on 30 Nov 1999,
PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8862

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 97 OF 135 USPATFULL on STN

AN 2002:250790 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN King, Gordon E., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

PI US 2002136728 A1 20020926

AI US 2001-920300 A1 20010731 (9)

PRAI US 2001-302051P 20010629 (60)

US 2001-279763P 20010328 (60)

US 2000-223283P 20000803 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6317

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly colon cancer, are disclosed. Illustrative compositions
comprise one or more colon tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 98 OF 135 USPATFULL on STN

AN 2002:243051 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES

Jones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002132237 A1 20020919

AI US 2001-867701 A1 20010529 (9)

PRAI US 2000-207484P 20000526 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 11
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 25718
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly ovarian cancer, are disclosed. Illustrative compositions
 comprise one or more ovarian tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 99 OF 135 USPATFULL on STN
 AN 2002:242791 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN King, Gordon E., Shoreline, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 Xu, Jiangchun, Bellevue, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
 PI US 2002131971 A1 20020919
 AI US 2001-33528 A1 20011226 (10)
 RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,
 PENDING
 PRAI US 2001-302051P 20010629 (60)
 US 2001-279763P 20010328 (60)
 US 2000-223283P 20000803 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 8083
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly colon cancer, are disclosed. Illustrative compositions
 comprise one or more colon tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 100 OF 135 USPATFULL on STN
 AN 2002:228456 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Benson, Darin R., Seattle, WA, UNITED STATES
 Mohamath, Raodoh, Seattle, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)
 PI US 2002123619 A1 20020905
 AI US 2001-960253 A1 20010920 (9)
 PRAI US 2000-234837P 20000922 (60)
 US 2000-239440P 20001010 (60)
 US 2001-301928P 20010629 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings

LN.CNT 8571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 101 OF 135 USPATFULL on STN

AN 2002:213763 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Kalos, Michael D., Seattle, WA, UNITED STATES

McNeill, Patricia D., Des Moines, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES

PI US 2002115139 A1 20020822

AI US 2001-850716 A1 20010507 (9)

RLI Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec 2000, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 13774

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 102 OF 135 USPATFULL on STN

AN 2002:206139 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Pyle, Ruth A., Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002110832 A1 20020815

AI US 2001-919580 A1 20010730 (9)

PRAI US 2001-302702P 20010703 (60)

US 2001-277495P 20010320 (60)

US 2000-237406P 20001002 (60)

US 2000-223265P 20000803 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L12 ANSWER 103 OF 135 USPATFULL on STN
 AN 2002:205876 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Reed, Steven G., Bellevue, WA, UNITED STATES
 Lodes, Michael J., Seattle, WA, UNITED STATES
 Mohamath, Raodoh, Seattle, WA, UNITED STATES
 Secrist, Heather, Seattle, WA, UNITED STATES
 Benson, Darin R., Seattle, WA, UNITED STATES
 Indirias, Carol Yoseph, Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 Fling, Steven P., Bainbridge Island, WA, UNITED STATES
 Algate, Paul A., Issaquah, WA, UNITED STATES
 Elliott, Mark, Seattle, WA, UNITED STATES
 Mannion, Jane, Edmonds, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 PI US 2002110563 A1 20020815
 AI US 2000-738973 A1 20001214 (9)
 RLI Continuation-in-part of Ser. No. US 2000-704512, filed on 1 Nov 2000,
 PENDING
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5236
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly lung cancer, are disclosed. Illustrative compositions
 comprise one or more lung tumor polypeptides, immunogenic portions
 thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 104 OF 135 USPATFULL on STN
 AN 2002:205860 USPATFULL
 TI Compounds for immunotherapy and diagnosis of colon cancer and methods
 for their use
 IN Wang, Aijun, Issaquah, WA, UNITED STATES
 Clapper, Jonathan D., Seattle, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
 PI US 2002110547 A1 20020815
 AI US 2001-833263 A1 20010410 (9)
 RLI Continuation-in-part of Ser. No. US 2000-649811, filed on 28 Aug 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-609448, filed on 29 Jun
 2000, PENDING Continuation-in-part of Ser. No. US 2000-575251, filed on
 19 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-519444,
 filed on 6 Mar 2000, PENDING Continuation-in-part of Ser. No. US
 2000-504629, filed on 15 Feb 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-480321, filed on 10 Jan 2000, PENDING Continuation-in-part
 of Ser. No. US 1999-476296, filed on 30 Dec 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-454150, filed on 2 Dec 1999,
 PENDING Continuation-in-part of Ser. No. US 2000-444252, filed on 10 Apr
 2000, PENDING Continuation-in-part of Ser. No. US 1999-401064, filed on
 22 Sep 1999, PENDING Continuation-in-part of Ser. No. US 1999-347496,
 filed on 2 Jul 1999, PENDING Continuation-in-part of Ser. No. US
 1998-221298, filed on 23 Dec 1998, GRANTED, Pat. No. US 6284241
 Continuation-in-part of Ser. No. WO 1999-US30909, filed on 23 Dec 1999,
 UNKNOWN
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings

LN.CNT 4619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 105 OF 135 USPATFULL on STN

AN 2002:171861 USPATFULL

TI Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

IN Hosken, Nancy A., Seattle, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
McGowan, Patrick, Seattle, WA, UNITED STATES
Sleath, Paul R., Seattle, WA, UNITED STATES

PI US 2002090610 A1 20020711

US 6537555 B2 20030325

AI US 2001-894998 A1 20010628 (9)

PRAI US 2001-277438P 20010320 (60)

US 2000-215458P 20000629 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.

L12 ANSWER 106 OF 135 USPATFULL on STN

AN 2002:164685 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
King, Gordon E., Shoreline, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES

PI US 2002086303 A1 20020704

AI US 2001-878134 A1 20010607 (9)

PRAI US 2000-210667P 20000609 (60)

US 2000-252614P 20001122 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor

protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 107 OF 135 USPATFULL on STN
AN 2002:164385 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002085998 A1 20020704
US 6680197 B2 20040120
AI US 2001-834759 A1 20010413 (9)
RLI Continuation-in-part of Ser. No. US 2000-620405, filed on 20 Jul 2000,
PENDING Continuation-in-part of Ser. No. US 2000-604287, filed on 22 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-590751, filed on
8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-551621,
filed on 17 Apr 2000, PENDING Continuation-in-part of Ser. No. US
1999-433826, filed on 3 Nov 1999, PENDING Continuation-in-part of Ser.
No. US 1999-389681, filed on 2 Sep 1999, PENDING Continuation-in-part of
Ser. No. US 1999-339338, filed on 23 Jun 1999, PENDING
Continuation-in-part of Ser. No. US 1999-285480, filed on 2 Apr 1999,
PENDING Continuation-in-part of Ser. No. US 1998-222575, filed on 28 Dec
1998, PENDING
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 12170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 108 OF 135 USPATFULL on STN
AN 2002:157603 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic
cancer
IN Hirst, Shannon K., Kirkland, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PI US 2002082207 A1 20020627
AI US 2001-872153 A1 20010531 (9)
PRAI US 2001-291197P 20010515 (60)
US 2000-248980P 20001114 (60)
US 2000-210329P 20000607 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

L12 ANSWER 109 OF 135 USPATFULL on STN

AN 2002:157081 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
de Bassols, Carlota Vinals, Rixensart, BELGIUM

PI US 2002081680 A1 20020627

AI US 2001-822827 A1 20010328 (9)

RLI Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb 2001,
PENDING Continuation-in-part of Ser. No. US 2000-679272, filed on 4 Oct
2000, PENDING

PRAI US 2000-157455P 20000417 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 7692

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 110 OF 135 USPATFULL on STN

AN 2002:157010 USPATFULL

TI Compositions and methods for the therapy and diagnosis of breast cancer

IN Dillon, Davin C., Issaquah, WA, UNITED STATES
Day, Craig H., Shoreline, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES

PI US 2002081609 A1 20020627

AI US 2001-910689 A1 20010720 (9)

RLI Continuation-in-part of Ser. No. US 2001-778320, filed on 6 Feb 2001,
PENDING Continuation-in-part of Ser. No. US 2000-571025, filed on 15 May
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-545068, filed
on 7 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-523586,
filed on 10 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-510662, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser.
No. US 1999-451651, filed on 30 Nov 1999, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8643

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 111 OF 135 USPATFULL on STN

AN 2002:148580 USPATFULL

TI Compositions and methods for the therapy and diagnosis of pancreatic
cancer

IN Pyle, Ruth A., Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002076721 A1 20020620

AI US 2001-923779 A1 20010806 (9)

PRAI US 2001-291201P 20010515 (60)

US 2001-265447P 20010130 (60)

US 2000-223130P 20000807 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6456

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly pancreatic cancer, are disclosed. Illustrative compositions
comprise one or more pancreatic tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly pancreatic cancer.

L12 ANSWER 112 OF 135 USPATFULL on STN

AN 2002:148277 USPATFULL

TI Compounds for immunotherapy and diagnosis of colon cancer and methods
for their use

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES

Lodes, Michael J., Seattle, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

Benson, Darin R., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Stolk, John A., Bothell, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

Jiang, Yuqiu, Kent, WA, UNITED STATES

Smith, Carole L., Seattle, WA, UNITED STATES

King, Gordon E., Shoreline, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Clapper, Jonathan D., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002076414 A1 20020620
AI US 2001-922217 A1 20010803 (9)
RLI Continuation-in-part of Ser. No. US 2001-833263, filed on 10 Apr 2001,
PENDING Continuation-in-part of Ser. No. US 2000-649811, filed on 28 Aug
2000, PENDING Continuation-in-part of Ser. No. US 2000-609448, filed on
29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-575251,
filed on 19 May 2000, PENDING Continuation-in-part of Ser. No. US
2000-519444, filed on 6 Mar 2000, PENDING Continuation-in-part of Ser.
No. US 2000-504629, filed on 15 Feb 2000, PENDING Continuation-in-part
of Ser. No. US 2000-480321, filed on 10 Jan 2000, ABANDONED
Continuation-in-part of Ser. No. US 1999-476296, filed on 30 Dec 1999,
PENDING Continuation-in-part of Ser. No. US 1999-454150, filed on 2 Dec
1999, ABANDONED Continuation-in-part of Ser. No. US 2000-444252, filed
on 10 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-401064,
filed on 22 Sep 1999, PENDING Continuation-in-part of Ser. No. US
1999-347496, filed on 2 Jul 1999, PENDING Continuation-in-part of Ser.
No. US 1998-221298, filed on 23 Dec 1998, PATENTED
PRAI WO 1999-US30909 19991223
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such
as colon cancer, are disclosed. Compositions may comprise one or more
colon tumor proteins, immunogenic portions thereof, or polynucleotides
that encode such portions. Alternatively, a therapeutic composition may
comprise an antigen presenting cell that expresses a colon tumor
protein, or a T cell that is specific for cells expressing such a
protein. Such compositions may be used, for example, for the prevention
and treatment of diseases such as colon cancer. Diagnostic methods based
on detecting a colon tumor protein, or mRNA encoding such a protein, in
a sample are also provided.

L12 ANSWER 113 OF 135 USPATFULL on STN
AN 2002:133437 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Lodes, Michael J., Seattle, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Mohamath, Raodoh, Seattle, WA, UNITED STATES
Indirias, Carol Yoseph, Seattle, WA, UNITED STATES
PI US 2002068288 A1 20020606
AI US 2001-833790 A1 20010411 (9)
PRAI US 2000-196780P 20000411 (60)
US 2000-213361P 20000621 (60)
US 2000-229763P 20000901 (60)
US 2000-230629P 20000905 (60)
US 2000-232565P 20000914 (60)
US 2000-257037P 20001219 (60)
US 2001-260796P 20010108 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 12418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly lung cancer, are disclosed. Illustrative compositions
comprise one or more lung tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed

compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 114 OF 135 USPATFULL on STN
AN 2002:133434 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Frudakis, Tony N., Sarasota, FL, UNITED STATES
Reed, Steven G., Bellevue, WA, UNITED STATES
Smith, John M., Columbia Heights, MN, UNITED STATES
Misher, Lynda E., Seattle, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
PI US 2002068285 A1 20020606
AI US 2001-810936 A1 20010316 (9)
RLI Continuation-in-part of Ser. No. US 2000-699295, filed on 26 Oct 2000,
PENDING Continuation-in-part of Ser. No. US 2000-590583, filed on 8 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-577505, filed on
24 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-534825,
filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US
1999-429755, filed on 28 Oct 1999, PENDING Continuation-in-part of Ser.
No. US 1999-289198, filed on 9 Apr 1999, PENDING Continuation-in-part of
Ser. No. US 1998-62451, filed on 17 Apr 1998, PENDING
Continuation-in-part of Ser. No. US 1997-991789, filed on 11 Dec 1997,
GRANTED, Pat. No. US 6225054 Continuation-in-part of Ser. No. US
1997-838762, filed on 9 Apr 1997, ABANDONED Continuation-in-part of Ser.
No. US 1996-700014, filed on 20 Aug 1996, ABANDONED Continuation-in-part
of Ser. No. US 1996-585392, filed on 11 Jan 1996, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 8540
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 115 OF 135 USPATFULL on STN
AN 2002:119860 USPATFULL
TI Compounds and methods for treatment and diagnosis of chlamydial
infection
IN Bhatia, Ajay, Seattle, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES
PI US 2002061848 A1 20020523
AI US 2001-841132 A1 20010423 (9)
RLI Continuation-in-part of Ser. No. US 2000-620412, filed on 20 Jul 2000,
UNKNOWN
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds and methods for the diagnosis and treatment of Chlamydial
infection are disclosed. The compounds provided include polypeptides

that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

L12 ANSWER 116 OF 135 USPATFULL on STN

AN 2002:99428 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES

Fan, Liqun, Bellevue, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Bangur, Chaitanya S., Seattle, WA, UNITED STATES

Hosken, Nancy A., Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Li, Samuel X., Redmond, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

McNeill, Patricia D., Des Moines, WA, UNITED STATES

Fanger, Neil, Seattle, WA, UNITED STATES

PI US 2002052329 A1 20020502

AI US 2000-735705 A1 20001212 (9)

RLI Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998, PENDING

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 13060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 117 OF 135 USPATFULL on STN

AN 2002:99081 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Mitcham, Jennifer L., Redmond, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Jiang, Yuqiu, Kent, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Retter, Marc W., Carnation, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Day, Craig H., Seattle, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Hural, John, Bainbridge Island, WA, UNITED STATES
McNeill, Patricia D., Des Moines, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES

PI US 2002051977 A1 20020502

AI US 2001-780669 A1 20010209 (9)

RLI Continuation-in-part of Ser. No. US 2001-759143, filed on 12 Jan 2001,
PENDING Continuation-in-part of Ser. No. US 2000-709729, filed on 9 Nov
2000, PENDING Continuation-in-part of Ser. No. US 2000-685166, filed on
10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426,
filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US
2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser.
No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part
of Ser. No. US 2000-636215, filed on 10 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000,
PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun
2000, PENDING Continuation-in-part of Ser. No. US 2000-510737, filed on
1 May 2000, GRANTED, Pat. No. US 6219981 Continuation-in-part of Ser.
No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of
Ser. No. US 2000-536857, filed on 27 Mar 2000, PENDING
Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000,
PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed
on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-352616,
filed on 13 Jul 1999, PENDING Continuation-in-part of Ser. No. US
1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser.
No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part
of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998,
PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb
1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US
1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562
Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997,
ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25
Feb 1997, ABANDONED Continuation-in-part of Ser. No. WO 1998-US3492,
filed on 25 Feb 1998, UNKNOWN Continuation-in-part of Ser. No. WO
1999-US15838, filed on 14 Jul 1999, UNKNOWN

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 7556

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly prostate cancer, are disclosed. Illustrative compositions
comprise one or more prostate-specific polypeptides, immunogenic
portions thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 118 OF 135 USPATFULL on STN

AN 2002:72987 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Jiang, Yuqiu, Kent, WA, UNITED STATES

Hepler, William T., Seattle, WA, UNITED STATES

Clapper, Jonathan D., Seattle, WA, UNITED STATES

Wang, Aijun, Issaquah, WA, UNITED STATES

Secrist, Heather, Seattle, WA, UNITED STATES

PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
US 2001-290240P 20010510 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8110

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 119 OF 135 USPATFULL on STN

AN 2002:55002 USPATFULL

TI Microspheres and adjuvants for DNA vaccine delivery

IN Johnson, Mark E., Bellevue, WA, UNITED STATES

Mossman, Sally, Seattle, WA, UNITED STATES

Cecil, Tricia, Bellevue, WA, UNITED STATES

Evans, Lawrence, Seattle, WA, UNITED STATES

PI US 2002032165 A1 20020314

AI US 2001-901829 A1 20010709 (9)

PRAI US 2000-216604P 20000707 (60)

DT Utility

FS APPLICATION

LREP GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER DRIVE WEST, SUITE
1050, LOS ANGELES, CA, 90045

CLMN Number of Claims: 57

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 1354

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A nucleic acid delivery system that offers, in one system, a combination of high encapsulation efficiency, rapid release kinetics and preservation of DNA in supercoiled form is provided. The nucleic acid delivery system comprises nucleic acid molecules, such as deoxyribonucleic acid (DNA), encapsulated in biodegradable microspheres, and is particularly suited for delivery of DNA vaccines. The invention further provides a method for encapsulating nucleic acid molecules in microspheres. The invention additionally provides a composition comprising nucleic acid molecules encapsulated in microspheres produced by a method of the invention, and a method for delivering a nucleic acid molecule to a subject. The invention further provides an adjuvant for modulating the immunostimulatory efficacy of microspheres encapsulating nucleic acid molecules comprising an aminoalkyl glucosamide 4-phosphate (AGP). The invention also provides a method for modulating the immunostimulatory efficacy of microspheres encapsulating nucleic acid molecules.

L12 ANSWER 120 OF 135 USPATFULL on STN

AN 2002:37531 USPATFULL

TI Compositions and methods for the therapy and diagnosis of prostate cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES

Dillon, Davin C., Issaquah, WA, UNITED STATES

Mitcham, Jennifer L., Redmond, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

Jiang, Yugu, Kent, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES
 Fanger, Gary R., Mill Creek, WA, UNITED STATES
 Retter, Marc W., Carnation, WA, UNITED STATES
 Stolk, John A., Bothell, WA, UNITED STATES
 Day, Craig H., Seattle, WA, UNITED STATES
 Vedvick, Thomas S., Federal Way, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Li, Samuel X., Redmond, WA, UNITED STATES
 Wang, Aijun, Issaquah, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Hepler, William T., Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 PI US 2002022248 A1 20020221
 AI US 2001-759143 A1 20010112 (9)
 RLI Continuation-in-part of Ser. No. US 2000-685166, filed on 10 Oct 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct
 2000, PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on
 6 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236,
 filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US
 2000-636215, filed on 10 Aug 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part
 of Ser. No. US 2000-593793, filed on 13 Jun 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-570737, filed on 12 May 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May
 2000, PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on
 27 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2000-483672,
 filed on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US
 1999-443686, filed on 18 Nov 1999, ABANDONED Continuation-in-part of
 Ser. No. US 1999-439313, filed on 12 Nov 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999,
 PENDING Continuation-in-part of Ser. No. US 1999-288946, filed on 9 Apr
 1999, PENDING Continuation-in-part of Ser. No. US 1999-232149, filed on
 15 Jan 1999, PENDING Continuation-in-part of Ser. No. US 1998-159812,
 filed on 23 Sep 1998, PENDING Continuation-in-part of Ser. No. US
 1998-115453, filed on 14 Jul 1998, PENDING Continuation-in-part of Ser.
 No. US 1998-30607, filed on 25 Feb 1998, GRANTED, Pat. No. US 6262245
 Continuation-in-part of Ser. No. US 1998-20956, filed on 9 Feb 1998,
 GRANTED, Pat. No. US 6261562 Continuation-in-part of Ser. No. US
 1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser.
 No. US 1997-806099, filed on 25 Feb 1997, ABANDONED
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 14 Drawing Page(s)
 LN.CNT 7383
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions and methods for the therapy and diagnosis of cancer,
 particularly prostate cancer, are disclosed. Illustrative compositions
 comprise one or more prostate-specific polypeptides, immunogenic
 portions thereof, polynucleotides that encode such polypeptides, antigen
 presenting cell that expresses such polypeptides, and T cells that are
 specific for cells expressing such polypeptides. The disclosed
 compositions are useful, for example, in the diagnosis, prevention
 and/or treatment of diseases, particularly prostate cancer.
 L12 ANSWER 121 OF 135 USPATFULL on STN
 AN 2002:16878 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Harlocker, Susan L., Seattle, WA, UNITED STATES
 Wang, Tongtong, Medina, WA, UNITED STATES
 Bangur, Chaitanya S., Seattle, WA, UNITED STATES
 Klee, Jennifer I., Seattle, WA, UNITED STATES
 Switzer, Ann, Seattle, WA, UNITED STATES
 PI US 2002009758 A1 20020124
 AI US 2001-866562 A1 20010525 (9)
 PRAI US 2000-207485P 20000526 (60)
 US 2000-230475P 20000906 (60)
 DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

L12 ANSWER 122 OF 135 USPATFULL on STN

AN 2002:16583 USPATFULL

TI FUSION PROTEINS OF ***MYCOBACTERIUM*** TUBERCULOSIS ANTIGENS AND THEIR USES

IN REED, STEVEN G., BELLEVUE, WA, UNITED STATES
SKEIKY, YASIR A., SEATTLE, WA, UNITED STATES
DILLON, DAVIN C., REDMOND, WA, UNITED STATES
ALDERSON, MARK, BAINBRIDGE ISLAND, WA, UNITED STATES
CAMPOS-NETO, ANTONIO, BAINBRIDGE, WA, UNITED STATES

PI US 2002009459 A1 20020124

US 6627198 B2 20030930

AI US 1999-287849 A1 19990407 (9)

RLI Continuation-in-part of Ser. No. US 1998-223040, filed on 30 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-56556, filed on 7 Apr 1998, PENDING Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-942578, filed on 1 Oct 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-818112, filed on 13 Mar 1997, GRANTED, Pat. No. US 6290969

DT Utility

FS APPLICATION

LREP ANNETTE S. PARENT, TOWNSEND AND TOWNSEND AND CREW LLP, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 47 Drawing Page(s)

LN.CNT 1524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to fusion proteins containing at least two ***Mycobacterium*** tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

L12 ANSWER 123 OF 135 USPATFULL on STN

AN 2002:8491 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Xu, Jiangchun, Bellevue, WA, UNITED STATES
Stolk, John A., Bothell, WA, UNITED STATES
Algate, Paul A., Issaquah, WA, UNITED STATES
Fling, Steven P., Bainbridge Island, WA, UNITED STATES

PI US 2002004491 A1 20020110

US 6710170 B2 20040323

AI US 2001-825294 A1 20010403 (9)

RLI Continuation-in-part of Ser. No. US 2000-713550, filed on 14 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-656668, filed on 7 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-640173, filed on 15 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-561778, filed on 1 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-394374, filed on 10 Sep 1999, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L12 ANSWER 124 OF 135 USPATFULL on STN

AN 2002:230962 USPATFULL

TI Compounds and methods for treatment and diagnosis of chlamydial
infection

IN Fling, Steven P., Bainbridge Island, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6448234 B1 20020910

AI US 2000-620412 20000720 (9)

RLI Continuation-in-part of Ser. No. US 2000-598419, filed on 20 Jun 2000
Continuation-in-part of Ser. No. US 2000-556877, filed on 19 Apr 2000
Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999
Continuation-in-part of Ser. No. US 1999-426571, filed on 22 Oct 1999
Continuation-in-part of Ser. No. US 1999-410568, filed on 1 Oct 1999
Continuation-in-part of Ser. No. US 1999-288594, filed on 8 Apr 1999
Continuation-in-part of Ser. No. US 1998-208277, filed on 8 Dec 1998,
now patented, Pat. No. US 6166177

DT Utility

FS GRANTED

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Li, O Janice

LREP Seed Intellectual Property Law Group PLLC

CLMN Number of Claims: 21

ECL Exemplary Claim: 10

DRWN 15 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 11681

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial
infection are disclosed. The compounds provided include polypeptides
that contain at least one antigenic portion of a Chlamydia antigen and
DNA sequences encoding such polypeptides. Pharmaceutical compositions
and vaccines comprising such polypeptides or DNA sequences are also
provided, together with antibodies directed against such polypeptides.
Diagnostic kits containing such polypeptides or DNA sequences and a
suitable detection reagent may be used for the detection of Chlamydial
infection in patients and in biological samples.

L12 ANSWER 125 OF 135 USPATFULL on STN

AN 2002:188122 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, United States

Fan, Liqun, Bellevue, WA, United States

Kalos, Michael D., Seattle, WA, United States

Bangur, Chaitanya S., Seattle, WA, United States

Hosken, Nancy A., Seattle, WA, United States

Fanger, Gary R., Mill Creek, WA, United States

Li, Samuel X., Redmond, WA, United States

Wang, Aijun, Issaquah, WA, United States

Skeiky, Yasir A. W., Bellevue, WA, United States

Henderson, Robert A., Edmonds, WA, United States

McNeill, Patricia D., Des Moines, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6426072 B1 20020730

AI US 2000-643597 20000821 (9)

RLI Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000

DT Utility

FS GRANTED

EXNAM Primary Examiner: Borin, Michael; Assistant Examiner: Zhou, Shubo
LREP Seed Intellectual Property Law Group PLLC
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 12270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L12 ANSWER 126 OF 135 USPATFULL on STN

AN 2002:39663 USPATFULL

TI Compositions and methods for the prevention and treatment of M. tuberculosis infection

IN Reed, Steven G., Bellevue, WA, United States

Skeiky, Yasir A. W., Seattle, WA, United States

Dillon, Davin C., Redmond, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6350456

B1 20020226

AI US 1998-56556

19980407 (9)

RLI Continuation-in-part of Ser. No. US 1998-25197, filed on 18 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1997-942578, filed on 1 Oct 1997, now abandoned Continuation-in-part of Ser. No. US 1997-818112, filed on 13 Mar 1997

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 6417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for treatment and vaccination against tuberculosis are disclosed. In one aspect the compositions provided include at least two polypeptides that contain an immunogenic portion of a M. tuberculosis antigen or at least two DNA molecules encoding such polypeptides. In a second aspect, the compositions provided include a fusion protein comprising at least two polypeptides that contain an immunogenic portion of a M. tuberculosis antigen. Such compositions may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

L12 ANSWER 127 OF 135 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 8

AN 2002:537954 BIOSIS

DN PREV200200537954

TI Human dendritic cells presenting adenovirally expressed antigen elicit ***Mycobacterium*** tuberculosis-specific CD8+ T cells.

AU Lewinsohn, Deborah A.; Lines, Rebecca A.; Lewinsohn, David M. [Reprint author]

CS Portland VA Medical Center, 3710 SW US Veterans Road, R and D 11, Portland, OR, 97201, USA
lewinsod@ohsu.edu

SO American Journal of Respiratory and Critical Care Medicine, (September 15, 2002) Vol. 166, No. 6, pp. 843-848. print.
ISSN: 1073-449X.

DT Article

LA English

ED Entered STN: 16 Oct 2002

Last Updated on STN: 16 Oct 2002

AB Previous studies in murine and human models have suggested an important

role for CD8+ T cells in host defense to ***Mycobacterium*** tuberculosis (Mtb). Consequently, a successful tuberculosis vaccine may require the elicitation of sustained CD4+ and CD8+ T cell responses. We tested the hypothesis that the potent CD4+ T cell antigen ***Mtb39*** is also a CD8+ T cell antigen. A recombinant adenovirus-expressing ***Mtb39*** (adenoMtb39) was used to infect monocyte-derived dendritic cells. Using interferon-gamma enzyme-linked immunospot, ***Mtb39***-specific CD8+ T lymphocytes were detected in three healthy individuals with latent tuberculosis infection who also had strong anti-***Mtb39***-specific CD4+ T cell responses. An ***Mtb39***-specific CD8+ T cell line was generated using ***Mtb39***-expressing dendritic cells. ***Mtb39***-specific T cell clones were obtained by limiting dilution cloning. All seven T cell clones obtained were HLA-B44 restricted. Using a panel of synthetic overlapping peptides representative of ***Mtb39***, the peptide epitope was identified for two clones. Furthermore, all T cell clones recognized Mtb-infected dendritic cells and were cytolytic. We conclude that infection of dendritic cells with adenoviral vectors expressing Mtb proteins allows for measurement of antigen-specific CD8+ T cell responses from peripheral blood mononuclear cells. The technique will be useful in defining CD8+ T cell antigens and in measuring immunogenicity of tuberculosis vaccines.

L12 ANSWER 128 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:731001 CAPLUS
 DN 135:284066
 TI Nucleic acids and proteins associated with human prostate cancer and their uses in therapy and diagnosis
 IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary Richard; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 579 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001073032	A2	20011004	WO 2001-US9919	20010327
	WO 2001073032	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6512094	B1	20030128	US 2000-593793	20000613
	US 6620922	B1	20030916	US 2000-636215	20000810
	US 6630305	B1	20031007	US 2000-685166	20001010
	AU 2001049549	A5	20011008	AU 2001-49549	20010327
	EP 1311673	A2	20030521	EP 2001-922786	20010327
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004504808	T2	20040219	JP 2001-570749	20010327
PRAI	US 2000-536857	A	20000327		
	US 2000-568100	A	20000509		
	US 2000-570737	A	20000512		
	US 2000-593793	A	20000613		
	US 2000-605783	A	20000627		
	US 2000-636215	A	20000810		
	US 2000-651236	A	20000829		
	US 2000-657279	A	20000906		
	US 2000-679426	A	20001002		
	US 2000-685166	A	20001010		
	US 2000-709729	A	20001109		
	US 1997-806099	B2	19970225		

US 1997-904804 B2 19970801
 US 1998-20956 A2 19980209
 US 1998-30607 A2 19980225
 US 1998-115453 A2 19980714
 US 1998-159812 A2 19980923
 US 1999-232149 A2 19990115
 US 1999-288946 A2 19990409
 US 1999-352616 A2 19990713
 US 1999-439313 A2 19991112
 US 1999-443686 B2 19991118
 US 2000-483672 A2 20000114
 US 2000-510737 A2 20000501
 WO 2001-US9919 W 20010327

AB Compsns. and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compsns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, and polynucleotides that encode such polypeptides as identified by PCR-based cDNA library subtraction. Chromosomal mapping, tissue expression profiling, and prepn. of fusion proteins (esp. with the Ral2 portion of the ***Mycobacterium*** tuberculosis serine protease ***MTB32A***) are carried out. Epitope mapping is carried out on some of the polypeptides (e.g., P501S) to identify immunogenic peptides. Antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides are also provided. The disclosed compsns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 129 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:526194 CAPLUS

DN 135:117956

TI Nucleic acids and polypeptides for the therapy and diagnosis of human prostate cancer

IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Reed, Steven G.; Kalos, Michael D.; Fanger, Gary Richard; Day, Craig H.; Retter, Marc W.; Stolk, John A.; Skeiky, Yasir A. W.; Wang, Aijun; Meagher, Madeleine Joy

PA Corixa Corporation, USA

SO PCT Int. Appl., 543 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051633	A2	20010719	WO 2001-US1574	20010116
	WO 2001051633	A3	20020620		
	WO 2001051633	C2	20021031		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1261708	A2	20021204	EP 2001-906582	20010116
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	BR 2001007643	A	20030610	BR 2001-7643	20010116
	JP 2003528591	T2	20030930	JP 2001-551207	20010116
	NO 2002003402	A	20020829	NO 2002-3402	20020715
PRAI	US 2000-483672	A	20000114		
	WO 2001-US1574	W	20010116		

AB Compsns. and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Several hundred prostate-specific polynucleotides (and their encoded polypeptides) are isolated from human prostate tumor cDNA libraries by cDNA library subtraction, PCR-based subtraction, electronic subtraction, and microarray anal. Illustrative compsns. comprise one or more prostate-specific polypeptides, immunogenic

portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that express such polypeptides, and T cells that are specific for cells expressing such polypeptides. Recombinant systems are described for the expression of such prostate-specific polypeptides in Escherichia coli, baculovirus, Saccharomyces cerevisiae, and mammalian cells. The disclosed compns. are useful, for example, in the diagnosis, prevention, and/or treatment of diseases, particularly prostate cancer.

L12 ANSWER 130 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:417155 CAPLUS

DN 135:45174

TI Antigenic compounds and methods for treatment and diagnosis of Chlamydial infection

IN Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Fling, Steven P.; Scholler, John

PA Corixa Corporation, USA

SO PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040474	A2	20010607	WO 2000-US32919	20001204
	WO 2001040474	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6432916	B1	20020813	US 2000-556877	20000419
	US 6565856	B1	20030520	US 2000-598419	20000620
	EP 1238084	A2	20020911	EP 2000-980969	20001204
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003515343	T2	20030507	JP 2001-542539	20001204
	BR 2000016066	A	20030610	BR 2000-16066	20001204
	NO 2002002592	A	20020719	NO 2002-2592	20020531
PRAI	US 1999-454684	A	19991203		
	US 2000-556877	A	20000419		
	US 2000-598419	A	20000620		
	US 1998-208277	A2	19981208		
	US 1999-288594	A2	19990408		
	US 1999-410568	A2	19991001		
	US 1999-426571	A2	19991022		
	WO 2000-US32919	W	20001204		

AB Compds. and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides from Chlamydia trachomatis and C. pneumoniae isolated using retroviral expression vector systems and subsequent immunol. anal. and epitope mapping. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples. In particular, fusion proteins are constructed from the Chlamydial proteins PmpA, PmpF, PmpH, PmpB, and PmpC fused with amino acid residues 192-323 of the Ra2 ***MTB32A*** serine proteinase from ***Mycobacterium*** tuberculosis.

L12 ANSWER 131 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:265565 CAPLUS

DN 134:291103

TI Methods of using a ***Mycobacterium*** tuberculosis coding sequence in gene and protein fusions to facilitate stable and high yield expression of heterologous proteins

IN Skeiky, Yasir; Guderian, Jeffrey
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025401	A2	20010412	WO 2000-US27652	20001006
	WO 2001025401	C2	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000079972	A5	20010510	AU 2000-79972	20001006
	JP 2003527830	T2	20030924	JP 2001-528556	20001006
PRAI	US 1999-158585P	P	19991007		
	WO 2000-US27652	W	20001006		

AB The present invention relates generally to nucleic acid and amino acid sequences of a fusion polypeptide comprising a ***Mycobacterium*** tuberculosis polypeptide, and a heterologous polypeptide of interest, expression vectors and host cells comprising such nucleic acids, and methods for producing such fusion polypeptides. In particular, the invention relates to materials and methods of using such M. tuberculosis sequence as a fusion partner to facilitate the stable and high yield expression of recombinant heterologous polypeptides of both eukaryotic and prokaryotic origin. A 14 kD C-terminal fragment (referred to as Ral2) of the ***Mycobacterium*** tuberculosis serine protease ***MTB32A*** can be expressed as a sol. protein. Use of the Ral2 sequences as a fusion partner is illustrated with construction of expression vectors, expression in Escherichia coli, and protein purifn. of a (His-tag) Ral2-DPPD fusion protein. Antiserum raised against the Ral2-DPPD fusion protein recognized the DPPD protein in immunoblotting anal. Ral2-WT1, Ral2-mammaglobin, and Ral2-H9-32A fusion proteins were also constructed and shorter or longer Ral2 sequences were fused with full length human mammaglobin gene sequences.

L12 ANSWER 132 OF 135 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:247369 CAPLUS

DN 134:279562

TI Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

IN Subjeck, John R.; Henderson, Robert A.; Repasky, Elizabeth A.; Kazim, Latif; Wang, Xiang-yang

PA Corixa Corporation, USA; Health Research, Inc.

SO PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023421	A2	20010405	WO 2000-US27023	20000929
	WO 2001023421	A3	20011025		
	WO 2001023421	C2	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

EP 1216055 A2 20020626 EP 2000-967198 20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003510334 T2 20030318 JP 2001-526571 20000929
PRAI US 1999-156821P P 19990930
US 1999-163138P P 19991102
US 2000-215497P P 20000630
WO 2000-US27023 W 20000929

AB Pharmaceutical compns. comprising a stress protein complex and related
mols. encoding or cells presenting such a complex are provided. The
stress protein complex comprises an hsp110 or grp170 polypeptide complexed
with an immunogenic polypeptide. The immunogenic polypeptide of the
stress protein complex can be assocd. with a cancer or an infectious
disease. The pharmaceutical compns. of the invention can be administered
to a subject, thereby providing methods for inhibiting M.
tuberculosis-infection, for inhibiting tumor growth, for inhibiting the
development of a cancer, and for the treatment or prevention of infectious
disease. The invention further provides a method for producing T cells
directed against a tumor cell or a M. tuberculosis-infected cell, wherein
a T cell is contacted with an APC that is modified to present an hsp110 or
grp170 polypeptide and an immunogenic polypeptide assocd. with a tumor or
with the M. tuberculosis-infected cell. Included in the the invention are
T cells produced by this method and a pharmaceutical compn. comprising
such T cells. The T cells can be contacted with aM. tuberculosis-infected
cell in a method for killing aM. tuberculosis-infected cell, or with a
tumor cell in a method for killing a tumor cell.

L12 ANSWER 133 OF 135 USPATFULL on STN
AN 2001:188420 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Dillon, Davin C., Issaquah, WA, United States
Day, Craig H., Seattle, WA, United States
Jiang, Yuqiu, Kent, WA, United States
Houghton, Raymond L., Bothell, WA, United States
Mitcham, Jennifer L., Redmond, WA, United States
Wang, Tongtong, Medina, WA, United States
McNeill, Patricia D., Des Moines, WA, United States
PI US 2001034052 A1 20011025
AI US 2001-778320 A1 20010206 (9)
RLI Continuation-in-part of Ser. No. US 2000-571025, filed on 15 May 2000,
PENDING Continuation-in-part of Ser. No. US 2000-545068, filed on 7 Apr
2000, PENDING Continuation-in-part of Ser. No. US 2000-523586, filed on
10 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2000-510662,
filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US
1999-451651, filed on 30 Nov 1999, PENDING
DT Utility
FS APPLICATION
LREP Jane E. R. Potter, Esq., Seed Intellectual Property Law Group PLLC,
Suite 6300, 701 Fifth Avenue, Seattle, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly breast cancer, are disclosed. Illustrative compositions
comprise one or more breast tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly breast cancer.

L12 ANSWER 134 OF 135 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 9
AN 1999:379686 BIOSIS
DN PREV199900379686
TI Cloning, expression, and immunological evaluation of two putative secreted
serine protease antigens of ***Mycobacterium*** tuberculosis.
AU Skeiky, Yasir A. W. [Reprint author]; Lodes, Michael J.; Guderian, Jeffrey
A.; Mohamath, Raodoh; Bement, Teresa; Alderson, Mark R.; Reed, Steven G.

CS Corixa Corporation, 1124 Columbia St., Seattle, WA, 98104, USA
SO Infection and Immunity, (Aug., 1999) Vol. 67, No. 8, pp. 3998-4007. print.
CODEN: INFIBR. ISSN: 0019-9567.

DT Article
LA English
OS Genbank-S47170; Genbank-U15180
ED Entered STN: 13 Sep 1999
Last Updated on STN: 13 Sep 1999

AB Culture filtrate proteins (CFP) of ***Mycobacterium*** tuberculosis have been shown to contain immunogenic components that elicit at least partial protective immunity against ***Mycobacterium*** infection. To clone genes encoding some of the immunogenic proteins, we made a high-titer rabbit anti-CFP serum and used it to screen an M. tuberculosis genomic expression library in Escherichia coli. In this paper, we describe the molecular cloning of two new protein components of CFP and identified them as members of the serine protease gene family. Their open reading frames contain N-terminal hydrophobic secretory signals consistent with their detection in CFP. The predicted molecular masses of the mature, fully processed forms of both antigens are approx 32 kDa, in agreement with their observed sizes on immunoblots of CFP probed with polyclonal rabbit antisera made to the recombinant proteins. Thus, these proteins have been designated ***MTB32A*** and MTB32B. Interestingly, and despite 66% amino acid sequence homology between the two proteins, polyclonal rabbit antisera made to each of the recombinant proteins were found to be specific for the respective immunizing antigens. The recombinant proteins were also evaluated in in vitro assays with donor peripheral blood mononuclear cells (PBMC) from healthy purified protein derivative (PPD)-positive individuals of diverse ethnic backgrounds. ***MTB32A*** but not MTB32B stimulated PBMC from healthy PPD-positive donors but not from PPD-negative donors to proliferate and secrete gamma interferon. ***MTB32A*** is encoded by a single-copy gene which is present in both virulent and avirulent strains of the M. tuberculosis complex and the BCG strain of ***Mycobacterium*** bovis but absent in the environmental ***mycobacterial*** species tested. In addition, nucleotide sequence comparison of ***mtb32a*** of the avirulent H37Ra strain and the virulent Erdman strain, as well as with the corresponding sequences (identified in the databases) of strain H37Rv and the clinical isolate CSU93, revealed 100% identity. ***MTB32A***, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during ***Mycobacterium*** spp. infection is discussed.

L12 ANSWER 135 OF 135 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 10

AN 1999:327567 BIOSIS
DN PREV199900327567

TI Molecular characterization and human T-Cell responses to a member of a novel ***Mycobacterium*** tuberculosis ***mtb39*** gene family.

AU Dillon, Davin C. [Reprint author]; Alderson, Mark R.; Day, Craig H.; Lewinsohn, David M.; Coler, Rhea; Bement, Teresa; Campos-Neto, Antonio; Skeiky, Y. A. W.; Orme, Ian M.; Roberts, Alan; Steen, Sean; Dalemans, Wilfried; Badaro, Roberto; Reed, Steven G.

CS Corixa Corporation, 1124 Columbia St., Suite 200, Seattle, WA, 98104, USA
SO Infection and Immunity, (June, 1999) Vol. 67, No. 6, pp. 2941-2950. print.
CODEN: INFIBR. ISSN: 0019-9567.

DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

AB We have used expression screening of a genomic ***Mycobacterium*** tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of M. tuberculosis and ***Mycobacterium*** bovis BCG but not in other ***mycobacterial*** species tested. Immunoblot analysis demonstrated the presence of Mtb39A in M. tuberculosis lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant

Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to M. tuberculosis CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from M. tuberculosis challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M. tuberculosis.

SECRET

FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS

Yasir Skeiky, a citizen of Canada and Lebanon, residing at
8327 25th Ave NW,
Seattle, WA 98107

Steven Reed, a citizen of the United States of America, residing at
2843 122nd Place NE
Bellevue, WA 98005

Mark Alderson, a citizen of Australia, residing at
1116 Grow Avenue, NW
Bainbridge Island, WA, 98116

Corixa Corporation
1124 Columbia St., Suite 200
Seattle, WA 98104

Express Mail No.
EL 827035345 US